

<!-- Created by Merrill Corporation -->
<!--Generated by IRIS Proton Version 4.0.2.8-->
<xbrli:xbrl xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:tbph="http://www.theravance.com/20140331" xmlns:us-gaap="http://fasb.org/us-gaap/2013-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2013-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:utr="http://www.xbrl.org/2009/utr">
  <link:schemaRef xlink:type="simple" xlink:href="tbph-20140331.xsd" />
  <xbrli:context id="D2014Q1">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001583107</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2014Q1">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001583107</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2013">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001583107</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2013Q1">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001583107</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2014Q1_TheravanceIncMember_EmployeeStockOptionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001583107</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tbph:TheravanceIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001583107</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2013Q1">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001583107</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2014Q1_MerckMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001583107</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">tbph:MerckMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2014Q1_RPharmCJSCMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001583107</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">tbph:RPharmCJSCMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2013Q1_MerckMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001583107</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">tbph:MerckMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2013Q1_RPharmCJSCMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001583107</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">tbph:RPharmCJSCMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2014Q1_AlfaWassermannMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001583107</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">tbph:AlfaWassermannMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2013Q1_AlfaWassermannMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001583107</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">tbph:AlfaWassermannMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2013Q1_M03_ClinigenMember_CommercializationAgreementMember_TheravanceIncMember_VIBATIVMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001583107</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">tbph:ClinigenMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tbph:CommercializationAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tbph:TheravanceIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">tbph:VIBATIVMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-03-01</xbrli:startDate>
      <xbrli:endDate>2013-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2013Q1_M03_ClinigenMember_CommercializationAgreementMember_TheravanceIncMember_MinimumMember_VIBATIVMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001583107</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">tbph:ClinigenMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tbph:CommercializationAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tbph:TheravanceIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">tbph:VIBATIVMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-03-01</xbrli:startDate>
      <xbrli:endDate>2013-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2013Q1_M03_CommercializationAgreementMember_ClinigenMember_TheravanceIncMember_MaximumMember_VIBATIVMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001583107</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">tbph:ClinigenMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tbph:CommercializationAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tbph:TheravanceIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">tbph:VIBATIVMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-03-01</xbrli:startDate>
      <xbrli:endDate>2013-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2014Q1_VIBATIVProductMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001583107</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">tbph:VIBATIVProductMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2011_TheravanceIncMember_SpecialLongTermRetentionAwards2011Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001583107</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tbph:TheravanceIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="tbph:IncentiveCompensationProgramAxis">tbph:SpecialLongTermRetentionAwards2011Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-01-01</xbrli:startDate>
      <xbrli:endDate>2011-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2014Q1_TheravanceIncMember_SpecialLongTermRetentionAwards2011Member_DeferredCashBonusMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001583107</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tbph:TheravanceIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="tbph:IncentiveCompensationProgramAxis">tbph:SpecialLongTermRetentionAwards2011Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis">tbph:DeferredCashBonusMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2014Q1_TheravanceIncMember_RestrictedStockMember_PerformanceContingentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001583107</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tbph:TheravanceIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:VestingAxis">tbph:PerformanceContingentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2011_TheravanceIncMember_RestrictedStockMember_PerformanceContingentMember_SpecialLongTermRetentionAwards2011Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001583107</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tbph:TheravanceIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:VestingAxis">tbph:PerformanceContingentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="tbph:AwardByPeriodAxis">tbph:SpecialLongTermRetentionAwards2011Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2011_TheravanceIncMember_RestrictedStockMember_PerformanceContingentMember_SpecialLongTermRetentionAwards2011Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001583107</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tbph:TheravanceIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:VestingAxis">tbph:PerformanceContingentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="tbph:AwardByPeriodAxis">tbph:SpecialLongTermRetentionAwards2011Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-01-01</xbrli:startDate>
      <xbrli:endDate>2011-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2014Q1_TheravanceIncMember_RestrictedStockMember_PerformanceContingentMember_SpecialLongTermRetentionAwards2011Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001583107</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tbph:TheravanceIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:VestingAxis">tbph:PerformanceContingentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="tbph:AwardByPeriodAxis">tbph:SpecialLongTermRetentionAwards2011Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2014Q1_ResearchAndDevelopmentExpenseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001583107</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2014Q1_SellingGeneralAndAdministrativeExpensesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001583107</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2013Q1_ResearchAndDevelopmentExpenseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001583107</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2013Q1_SellingGeneralAndAdministrativeExpensesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001583107</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2013Q1_TheravanceIncMember_EmployeeStockOptionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001583107</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tbph:TheravanceIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2014Q2SO">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001583107</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-06-06</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2014Q2_5M_TheravanceIncMember_RestrictedStockMember_PerformanceContingentMember_SpecialLongTermRetentionAwards2011Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001583107</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tbph:TheravanceIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:VestingAxis">tbph:PerformanceContingentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="tbph:AwardByPeriodAxis">tbph:SpecialLongTermRetentionAwards2011Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-05-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2014Q2_M05_TheravanceIncMember_RestrictedStockMember_PerformanceContingentMember_SpecialLongTermRetentionAwards2011Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001583107</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tbph:TheravanceIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:VestingAxis">tbph:PerformanceContingentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="tbph:AwardByPeriodAxis">tbph:SpecialLongTermRetentionAwards2011Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-05-01</xbrli:startDate>
      <xbrli:endDate>2014-05-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2014Q2_M05_TheravanceIncMember_SpecialLongTermRetentionAwards2011Member_DeferredCashBonusMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001583107</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tbph:TheravanceIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="tbph:IncentiveCompensationProgramAxis">tbph:SpecialLongTermRetentionAwards2011Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis">tbph:DeferredCashBonusMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-05-01</xbrli:startDate>
      <xbrli:endDate>2014-05-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2014Q2_M0601_SubsequentEventMember_SeparationAndDistributionAgreementMember_TheravanceIncMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001583107</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tbph:SeparationAndDistributionAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">tbph:TheravanceIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-05-30</xbrli:startDate>
      <xbrli:endDate>2014-06-01</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2014Q2_M0602_SubsequentEventMember_TransitionServicesAgreementMember_TheravanceIncMember_MaximumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001583107</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tbph:TransitionServicesAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">tbph:TheravanceIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-05-30</xbrli:startDate>
      <xbrli:endDate>2014-06-02</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2014Q2_M0602_SubsequentEventMember_TransitionServicesAgreementMember_TheravanceIncMember_MinimumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001583107</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tbph:TransitionServicesAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">tbph:TheravanceIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-05-30</xbrli:startDate>
      <xbrli:endDate>2014-06-02</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2014Q2_M0602">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001583107</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-05-30</xbrli:startDate>
      <xbrli:endDate>2014-06-02</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2014Q2_M0531_TheravanceIncMember_RestrictedStockMember_PerformanceContingentMember_SpecialLongTermRetentionAwards2011Member_MaximumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001583107</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tbph:TheravanceIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:VestingAxis">tbph:PerformanceContingentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="tbph:AwardByPeriodAxis">tbph:SpecialLongTermRetentionAwards2011Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-05-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:unit id="USD">
    <xbrli:measure>iso4217:USD</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="Shares">
    <xbrli:measure>xbrli:shares</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="Pure">
    <xbrli:measure>xbrli:pure</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="Item">
    <xbrli:measure>tbph:Item</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="USDPerShare">
    <xbrli:divide>
      <xbrli:unitNumerator>
        <xbrli:measure>iso4217:USD</xbrli:measure>
      </xbrli:unitNumerator>
      <xbrli:unitDenominator>
        <xbrli:measure>xbrli:shares</xbrli:measure>
      </xbrli:unitDenominator>
    </xbrli:divide>
  </xbrli:unit>
  <us-gaap:CollaborativeArrangementDisclosureTextBlock id="Tag1" contextRef="D2014Q1">&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2"&gt;2. Collaborative Arrangements&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;b&gt;&lt;i&gt;&lt;font style="FONT-STYLE: italic; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2"&gt;Revenue from Collaborative Arrangements&lt;/font&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;We recognized revenue from collaborative arrangements as follows:&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="text-align:left;WIDTH: 96.66%; BORDER-COLLAPSE: collapse;" border="0" cellspacing="0" cellpadding="0" width="96%"&gt;

&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 68.96%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="68%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.58%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 27.42%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="27%" colspan="5"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;Three&amp;#160;Months&amp;#160;Ended&amp;#160;March&amp;#160;31,&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.04%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 68.96%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="68%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;(In&amp;#160;thousands)&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.58%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.42%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;2014&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.58%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.42%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;2013&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.04%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 68.96%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="68%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Merck&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.58%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="11%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.58%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="11%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;5&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.04%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 68.96%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="68%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;R-Pharm CJSC&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.58%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.42%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.58%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.42%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;17&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.04%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 68.96%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="68%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Total revenue from collaborative arrangements&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.58%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="11%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.58%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="11%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;22&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.04%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;b&gt;&lt;i&gt;&lt;font style="FONT-STYLE: italic; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2"&gt;Clinigen Group&lt;/font&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;i&gt;&lt;font style="FONT-STYLE: italic; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Commercialization Agreement&lt;/font&gt;&lt;/i&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;In March&amp;#160;2013, Theravance entered into a commercialization agreement (the &amp;#8220;Clinigen Commercialization Agreement&amp;#8221;) with Clinigen Group&amp;#160;plc (&amp;#8220;Clinigen&amp;#8221;) to commercialize VIBATIV&lt;/font&gt;&lt;font style="POSITION: relative; FONT-SIZE: 6.5pt; TOP: -3pt;" size="1"&gt;&amp;#174;&lt;/font&gt;&lt;font style="FONT-SIZE: 10pt;" size="2"&gt;&amp;#160;for the treatment of hospital acquired nosocomial pneumonia, including ventilator-associated pneumonia, known or suspected to be caused by methicillin resistant &lt;i&gt;Staphylococcus aureus&lt;/i&gt; (MRSA) when other alternatives are not suitable. Under the agreement, Theravance granted Clinigen exclusive commercialization rights in the European Union and certain other European countries (including Switzerland and Norway). Theravance received a $5.0&amp;#160;million (unaudited) upfront payment in March&amp;#160;2013. This agreement was assigned to us in the Spin-Off, and we will now be eligible to receive tiered royalty payments on net sales of VIBATIV&lt;/font&gt;&lt;font style="POSITION: relative; FONT-SIZE: 6.5pt; TOP: -3pt;" size="1"&gt;&amp;#174;&lt;/font&gt;&lt;font style="FONT-SIZE: 10pt;" size="2"&gt;, ranging from 20% to 30%. We are responsible, either directly or through our vendors or contractors, for supplying at Clinigen&amp;#8217;s expense both API and finished drug product for Clinigen&amp;#8217;s commercialization activities. The agreement has a term of at least 15&amp;#160;years, with an option to extend exercisable by Clinigen. However, Clinigen may terminate the agreement at any time after it has initiated commercialization upon 12&amp;#160;months&amp;#8217; advance notice.&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Under the Clinigen Commercialization Agreement, the significant deliverables were determined to be the license, committee participation and manufacturing supply. Theravance determined that the license represents a separate unit of accounting as the license, which includes rights to Theravance&amp;#8217;s underlying technologies for VIBATIV&lt;/font&gt;&lt;font style="POSITION: relative; FONT-SIZE: 6.5pt; TOP: -3pt;" size="1"&gt;&amp;#174;&lt;/font&gt;&lt;font style="FONT-SIZE: 10pt;" size="2"&gt;, has standalone value because the rights conveyed permit Clinigen to perform all efforts necessary to use Theravance&amp;#8217;s technologies to bring the compound through commercialization and based the best estimate of selling price for the license based on potential future cash flows under the arrangement over the estimated commercialization period. Theravance determined that the committee participation represents a separate unit of accounting as Clinigen could negotiate for and/or acquire these services from other third parties and based the best estimate of selling price of the committee participation based on the nature and timing of the services to be performed. Theravance determined the best estimate of selling price for the manufacturing supply based on a fully burdened cost to purchase and transfer the underlying API and finished goods from Theravance&amp;#8217;s third party contract manufacturer. The license, committee representation and supply obligations under the&amp;#160; Clinigen Commercialization Agreement are now our obligations.&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;The $5.0&amp;#160;million upfront payment received by Theravance was allocated to two units of accounting based on the relative selling price method as follows: $4.9&amp;#160;million to the license and $0.1&amp;#160;million to the committee participation. Theravance did not recognize any revenue from the license and committee participation as the technical transfer activities were not completed as of March&amp;#160;31, 2014 and the associated units of accounting were not delivered. The amount of the upfront payment allocated to the committee participation was deferred and will be recognized as revenue over the estimated performance period. Amounts received under a future separate supply agreement for API and finished goods, which will be manufactured by our third party contract manufacturers, will be recognized as revenue to the extent of future API and finished goods inventory sales.&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;b&gt;&lt;i&gt;&lt;font style="FONT-STYLE: italic; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2"&gt;Reimbursement of R&amp;amp;D Costs&lt;/font&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Under certain collaborative arrangements, we are entitled to reimbursement of certain R&amp;amp;D costs. Our policy is to account for the reimbursement payments by our collaboration partners as reductions to R&amp;amp;D expense.&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;The following table summarizes the reductions to R&amp;amp;D expenses related to the reimbursement payments:&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="text-align:left;WIDTH: 96.66%; BORDER-COLLAPSE: collapse;" border="0" cellspacing="0" cellpadding="0" width="96%"&gt;

&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 68.96%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="68%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.58%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 27.42%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="27%" colspan="5"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;Three&amp;#160;Months&amp;#160;Ended&amp;#160;March&amp;#160;31,&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.04%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 68.96%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="68%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;(In&amp;#160;thousands)&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.58%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.42%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;2014&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.58%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.42%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;2013&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.04%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 68.96%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="68%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Merck&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.58%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.34%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.08%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="11%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.58%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.34%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.08%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="11%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;1,429&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.04%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 68.96%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="68%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Alfa Wassermann societ&amp;#224; per azioni&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.58%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.42%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;72&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.58%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.42%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;208&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.04%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 68.96%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="68%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;R-Pharm CJSC&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.58%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.42%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;18&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.58%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.42%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;326&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.04%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 68.96%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="68%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Total reduction to R&amp;amp;D expense&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.58%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.34%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.08%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="11%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;90&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.58%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.34%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.08%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="11%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;1,963&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.04%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
  <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock id="Tag2" contextRef="D2014Q1">&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2"&gt;4. Share-Based Compensation&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;As of March&amp;#160;31, 2014, we had not issued any share-based awards to our employees. We have adopted an equity incentive plan that provides for the grant of equity-based awards, including restricted shares, restricted share units, options, share appreciation rights and other equity-based awards, to our directors, officers and other employees and advisors.&amp;#160;Shortly after the spin-off, we granted share options to our directors pursuant to our outside director automatic grant program and to our employees joining Theravance Biopharma.&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Our employees have in the past received Theravance share-based compensation awards, and therefore, the following disclosures pertain to share-based compensation that has been allocated to Theravance Biopharma related to Theravance stock-based equity awards. Accordingly, the amounts presented are not necessarily indicative of future performance and do not necessarily reflect the results that we would have experienced as an independent, publicly-traded company for the periods presented.&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;b&gt;&lt;i&gt;&lt;font style="FONT-STYLE: italic; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2"&gt;Performance-Contingent Restricted Stock Awards&lt;/font&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Over the past three years, the Compensation Committee of Theravance&amp;#8217;s Board of Directors (the &amp;#8220;Compensation Committee&amp;#8221;) has approved grants of performance-contingent RSAs to senior management and a non-executive officer.&amp;#160; Generally, these awards have dual triggers of vesting based upon the achievement of certain performance goals by a pre-specified date, as well as a requirement for continued employment.&amp;#160; When the performance goals are deemed achieved for these types of awards, time-based vesting and, as a result, recognition of stock-based compensation expense commence. Included in these performance-contingent RSAs is the grant of 1,290,000 special long-term retention and incentive performance-contingent RSAs to senior management in 2011.&amp;#160; The awards have dual triggers of vesting based upon the achievement of certain performance conditions over a six-year timeframe from 2011 through December&amp;#160;31, 2016 and require continued employment.&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;As of March&amp;#160;31, 2014, Theravance determined that the achievement of the requisite performance conditions for vesting of the first tranche of awards was probable and, as a result, $6.8 million of stock-based compensation expense was recognized by us in the first quarter of 2014. The total stock-based compensation expense of $7.0 million for the first tranche was recognized through May&amp;#160;2014.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;In May&amp;#160;2014, the Compensation Committee approved the modification of the remaining tranches related to this grant contingent upon the Spin-Off. The modification acknowledged the Spin-Off and permitted recognition of achievement of the original performance conditions that were met prior to the Spin-Off, triggering service-based vesting for a portion of the equity awards. The remaining tranches of the equity awards remain subject to performance and service conditions. The maximum remaining potential stock-based compensation expense associated with these awards after the modification is $24.5&amp;#160;million, of which $10.7 million will be recognized by either Theravance or us, based on which company employs the individuals who hold these awards during the twelve-month service period commencing in June&amp;#160;2014.&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;b&gt;&lt;i&gt;&lt;font style="FONT-STYLE: italic; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2"&gt;Stock-Based Compensation Expense&lt;/font&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;The allocation of stock-based compensation expense included in the condensed combined statements of operations and comprehensive loss was as follows:&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="text-align:left;WIDTH: 96.66%; BORDER-COLLAPSE: collapse;" border="0" cellspacing="0" cellpadding="0" width="96%"&gt;

&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 68.96%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="68%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.58%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 27.42%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="27%" colspan="5"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;Three&amp;#160;Months&amp;#160;Ended&amp;#160;March&amp;#160;31,&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.04%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 68.96%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="68%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;(In&amp;#160;thousands)&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.58%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.42%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;2014&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.58%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.42%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;2013&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.04%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 68.96%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="68%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Research and development&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.58%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.34%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.08%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="11%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;4,721&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.58%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.34%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.08%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="11%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;3,688&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.04%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 68.96%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="68%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Selling, general and administrative&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.58%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.42%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;7,980&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.58%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.42%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;1,828&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.04%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 68.96%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="68%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Total stock-based compensation expense&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.58%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.34%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.08%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="11%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;12,701&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.58%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.34%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.08%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="11%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;5,516&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.04%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Total stock-based compensation expense capitalized to inventory was not material for the three months ended March&amp;#160;31, 2014 and 2013.&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;b&gt;&lt;i&gt;&lt;font style="FONT-STYLE: italic; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2"&gt;Valuation Assumptions&lt;/font&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;The range of weighted-average assumptions Theravance used to estimate the fair value of stock options granted was as follows:&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="text-align:left;WIDTH: 100%; BORDER-COLLAPSE: collapse;" border="0" cellspacing="0" cellpadding="0" width="100%"&gt;

&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 70%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="70%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 26.5%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="26%" colspan="5"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;Three&amp;#160;Months&amp;#160;Ended&lt;br /&gt;
March&amp;#160;31,&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 70%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="70%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;2014&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;2013&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 70%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="70%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;b&gt;&lt;i&gt;&lt;font style="FONT-STYLE: italic; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2"&gt;Employee stock options&lt;/font&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 70%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="70%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Risk-free interest rate&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;1.8-2.0&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;%&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;1.0%-1.1&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;%&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 70%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="70%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Expected term (in years)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;6&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;6&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 70%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="70%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Volatility&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;60&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;%&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;58&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;%&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 70%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="70%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Dividend yield&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;%&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;%&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 70%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="70%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Weighted-average estimated fair value of stock options granted&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.7%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="10%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;21.29&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.7%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="10%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;12.32&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; BORDER-TOP: medium none; BORDER-RIGHT: medium none;" width="523"&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; BORDER-TOP: medium none; BORDER-RIGHT: medium none;" width="18"&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; BORDER-TOP: medium none; BORDER-RIGHT: medium none;" width="9"&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; BORDER-TOP: medium none; BORDER-RIGHT: medium none;" width="80"&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; BORDER-TOP: medium none; BORDER-RIGHT: medium none;" width="18"&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; BORDER-TOP: medium none; BORDER-RIGHT: medium none;" width="9"&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; BORDER-TOP: medium none; BORDER-RIGHT: medium none;" width="80"&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; BORDER-TOP: medium none; BORDER-RIGHT: medium none;" width="11"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
  <us-gaap:IncomeTaxExpenseBenefit id="Tag3" contextRef="D2014Q1" unitRef="USD" decimals="0">0</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:IncomeTaxDisclosureTextBlock id="Tag4" contextRef="D2014Q1">&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2"&gt;5. Income Taxes&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;We account for income taxes on a separate tax return basis although our operations have historically been included in the tax returns filed by Theravance. Due to ongoing operating losses and the inability to recognize any income tax benefit, there is no provision for income taxes for any periods presented.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
  <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent id="Tag5" contextRef="I2014Q1" unitRef="USD" decimals="-3">833000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
  <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent id="Tag6" contextRef="I2013" unitRef="USD" decimals="-3">833000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
  <us-gaap:PropertyPlantAndEquipmentNet id="Tag7" contextRef="I2014Q1" unitRef="USD" decimals="-3">9734000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:PropertyPlantAndEquipmentNet id="Tag8" contextRef="I2013" unitRef="USD" decimals="-3">10238000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:Assets id="Tag9" contextRef="I2014Q1" unitRef="USD" decimals="-3">26167000</us-gaap:Assets>
  <us-gaap:Assets id="Tag10" contextRef="I2013" unitRef="USD" decimals="-3">25177000</us-gaap:Assets>
  <us-gaap:AccountsPayableCurrent id="Tag11" contextRef="I2014Q1" unitRef="USD" decimals="-3">4984000</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccountsPayableCurrent id="Tag12" contextRef="I2013" unitRef="USD" decimals="-3">6940000</us-gaap:AccountsPayableCurrent>
  <us-gaap:EmployeeRelatedLiabilitiesCurrent id="Tag13" contextRef="I2014Q1" unitRef="USD" decimals="-3">13417000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
  <us-gaap:EmployeeRelatedLiabilitiesCurrent id="Tag14" contextRef="I2013" unitRef="USD" decimals="-3">9870000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
  <us-gaap:OtherAccruedLiabilitiesCurrent id="Tag15" contextRef="I2014Q1" unitRef="USD" decimals="-3">9890000</us-gaap:OtherAccruedLiabilitiesCurrent>
  <us-gaap:OtherAccruedLiabilitiesCurrent id="Tag16" contextRef="I2013" unitRef="USD" decimals="-3">9714000</us-gaap:OtherAccruedLiabilitiesCurrent>
  <us-gaap:OtherLiabilitiesCurrent id="Tag17" contextRef="I2014Q1" unitRef="USD" decimals="-3">2521000</us-gaap:OtherLiabilitiesCurrent>
  <us-gaap:OtherLiabilitiesCurrent id="Tag18" contextRef="I2013" unitRef="USD" decimals="-3">2122000</us-gaap:OtherLiabilitiesCurrent>
  <us-gaap:DeferredRevenueCurrent id="Tag19" contextRef="I2014Q1" unitRef="USD" decimals="-3">7732000</us-gaap:DeferredRevenueCurrent>
  <us-gaap:DeferredRevenueCurrent id="Tag20" contextRef="I2013" unitRef="USD" decimals="-3">8207000</us-gaap:DeferredRevenueCurrent>
  <us-gaap:LiabilitiesCurrent id="Tag21" contextRef="I2014Q1" unitRef="USD" decimals="-3">38544000</us-gaap:LiabilitiesCurrent>
  <us-gaap:LiabilitiesCurrent id="Tag22" contextRef="I2013" unitRef="USD" decimals="-3">36853000</us-gaap:LiabilitiesCurrent>
  <us-gaap:DeferredRentCreditNoncurrent id="Tag23" contextRef="I2014Q1" unitRef="USD" decimals="-3">4891000</us-gaap:DeferredRentCreditNoncurrent>
  <us-gaap:DeferredRentCreditNoncurrent id="Tag24" contextRef="I2013" unitRef="USD" decimals="-3">4774000</us-gaap:DeferredRentCreditNoncurrent>
  <us-gaap:DeferredRevenueNoncurrent id="Tag25" contextRef="I2014Q1" unitRef="USD" decimals="-3">648000</us-gaap:DeferredRevenueNoncurrent>
  <us-gaap:DeferredRevenueNoncurrent id="Tag26" contextRef="I2013" unitRef="USD" decimals="-3">585000</us-gaap:DeferredRevenueNoncurrent>
  <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock id="Tag27" contextRef="D2014Q1">&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2"&gt;6. Commitments and Contingencies&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;b&gt;&lt;i&gt;&lt;font style="FONT-STYLE: italic; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2"&gt;Special Long-Term Retention and Incentive Cash Awards Program&lt;/font&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;In 2011, Theravance granted special long-term retention and incentive cash bonus awards to certain employees. The awards have dual triggers of vesting based upon the achievement of certain performance conditions over a six-year timeframe from 2011 through December&amp;#160;31, 2016 and continued employment.&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;As of March&amp;#160;31, 2014, Theravance&amp;#8217;s management determined that the achievement of the requisite performance conditions for the first tranche of awards was probable and, as a result, $9.1 million of cash bonus expense was recognized by us in the first quarter of 2014. In May&amp;#160;2014, the total cash bonus of $9.5 million for the first tranche was paid.&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;In May&amp;#160;2014, the Compensation Committee approved the modification of the remaining tranches related to this grant contingent upon the Spin-Off. The modification acknowledged the Spin-Off and permitted recognition of achievement of the original performance conditions that were met prior to the Spin-Off, triggering service-based vesting for a portion of the cash awards. The remaining tranches of the cash awards were forfeited. The maximum remaining potential cash bonus expense associated with these cash bonus awards after the modification is $11.2&amp;#160;million, the majority of which will be recognized by us over a twelve-month service period commencing in June&amp;#160;2014.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
  <us-gaap:CommitmentsAndContingencies id="Tag28" contextRef="I2013" unitRef="USD" xsi:nil="true" />
  <us-gaap:CommitmentsAndContingencies id="Tag29" contextRef="I2014Q1" unitRef="USD" xsi:nil="true" />
  <us-gaap:StockholdersEquity id="Tag30" contextRef="I2014Q1" unitRef="USD" decimals="-3">-17916000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="Tag31" contextRef="I2013" unitRef="USD" decimals="-3">-17035000</us-gaap:StockholdersEquity>
  <us-gaap:LiabilitiesAndStockholdersEquity id="Tag32" contextRef="I2014Q1" unitRef="USD" decimals="-3">26167000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:LiabilitiesAndStockholdersEquity id="Tag33" contextRef="I2013" unitRef="USD" decimals="-3">25177000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:SalesRevenueGoodsNet id="Tag34" contextRef="D2014Q1" unitRef="USD" decimals="-3">945000</us-gaap:SalesRevenueGoodsNet>
  <us-gaap:OperatingExpenses id="Tag35" contextRef="D2014Q1" unitRef="USD" decimals="-3">60963000</us-gaap:OperatingExpenses>
  <us-gaap:OperatingExpenses id="Tag36" contextRef="D2013Q1" unitRef="USD" decimals="-3">32196000</us-gaap:OperatingExpenses>
  <us-gaap:Revenues id="Tag37" contextRef="D2014Q1" unitRef="USD" decimals="-3">945000</us-gaap:Revenues>
  <us-gaap:Revenues id="Tag38" contextRef="D2013Q1" unitRef="USD" decimals="-3">22000</us-gaap:Revenues>
  <us-gaap:CostOfGoodsSold id="Tag39" contextRef="D2014Q1" unitRef="USD" decimals="-3">188000</us-gaap:CostOfGoodsSold>
  <us-gaap:SubsequentEventsTextBlock id="Tag40" contextRef="D2014Q1">&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2"&gt;7. Subsequent Events&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;The Spin-Off was effected pursuant to a Separation and Distribution Agreement dated June&amp;#160;1, 2014, which provides, among other things, for the principal corporate transactions required to effect the Spin-Off and certain other agreements governing Theravance&amp;#8217;s relationship with us after the Spin-Off. These agreements are discussed below.&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;b&gt;&lt;i&gt;&lt;font style="FONT-STYLE: italic; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2"&gt;Separation and Distribution Agreement&lt;/font&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;In connection with the Spin-Off, on June&amp;#160;1, 2014, Theravance and Theravance Biopharma entered into the Separation and Distribution Agreement.&amp;#160; The Separation and Distribution Agreement identifies the assets transferred, liabilities assumed and contracts assigned to us as part of the Spin-Off, and describes when and how these transfers, assumptions and assignments will occur.&amp;#160; In particular, all of the assets and liabilities associated or primarily used in connection with the drug discovery and development business operations were transferred to us, including:&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: -0.25in; MARGIN: 0in 0in 0pt 0.5in;"&gt;&lt;font style="FONT-FAMILY: Symbol; FONT-SIZE: 10pt;" size="2"&gt;&amp;#183;&lt;/font&gt;&lt;font style="FONT-SIZE: 3pt;" size="1"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt; &lt;font style="FONT-SIZE: 10pt;" size="2"&gt;VIBATIV&lt;/font&gt;&lt;font style="POSITION: relative; FONT-SIZE: 6.5pt; TOP: -3pt;" size="1"&gt;&amp;#174;&lt;/font&gt;&lt;font style="FONT-SIZE: 10pt;" size="2"&gt;&amp;#160;(telavancin), a bactericidal, once daily injectable antibiotic;&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: -0.25in; MARGIN: 0in 0in 0pt 0.5in;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: -0.25in; MARGIN: 0in 0in 0pt 0.5in;"&gt;&lt;font style="FONT-FAMILY: Symbol; FONT-SIZE: 10pt;" size="2"&gt;&amp;#183;&lt;/font&gt;&lt;font style="FONT-SIZE: 3pt;" size="1"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt; &lt;font style="FONT-SIZE: 10pt;" size="2"&gt;Our small molecule product candidate pipeline currently focused on bacterial infections, CNS/pain, respiratory disease, and GI motility dysfunction; and&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: -0.25in; MARGIN: 0in 0in 0pt 0.5in;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: -0.25in; MARGIN: 0in 0in 0pt 0.5in;"&gt;&lt;font style="FONT-FAMILY: Symbol; FONT-SIZE: 10pt;" size="2"&gt;&amp;#183;&lt;/font&gt;&lt;font style="FONT-SIZE: 3pt;" size="1"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt; &lt;font style="FONT-SIZE: 10pt;" size="2"&gt;A portion of the equity interests in Theravance Respiratory Company, LLC, which will entitle us to receive 85% of the economic interest in any future payments made by GSK under the various GSK agreements relating to UMEC/VI/FF and the MABA program, as monotherapy and in combination with other therapeutically active components, such as an inhaled corticosteroid (ICS), and any other product or combination of products that may be discovered and developed in the future under the GSK agreements (other than RELVAR&lt;/font&gt;&lt;font style="POSITION: relative; FONT-SIZE: 6.5pt; TOP: -3pt;" size="1"&gt;&amp;#174;&lt;/font&gt;&lt;font style="FONT-SIZE: 10pt;" size="2"&gt;/ELLIPTA&lt;/font&gt;&lt;font style="POSITION: relative; FONT-SIZE: 6.5pt; TOP: -3pt;" size="1"&gt;&amp;#174;&lt;/font&gt;&lt;font style="FONT-SIZE: 10pt;" size="2"&gt;, BREO&lt;/font&gt;&lt;font style="POSITION: relative; FONT-SIZE: 6.5pt; TOP: -3pt;" size="1"&gt;&amp;#174;&lt;/font&gt;&lt;font style="FONT-SIZE: 10pt;" size="2"&gt;/ELLIPTA&lt;/font&gt;&lt;font style="POSITION: relative; FONT-SIZE: 6.5pt; TOP: -3pt;" size="1"&gt;&amp;#174;&lt;/font&gt;&lt;font style="FONT-SIZE: 10pt;" size="2"&gt;, ANORO&lt;/font&gt;&lt;font style="POSITION: relative; FONT-SIZE: 6.5pt; TOP: -3pt;" size="1"&gt;&amp;#8482;&lt;/font&gt;&lt;font style="FONT-SIZE: 10pt;" size="2"&gt;&amp;#160;ELLIPTA&lt;/font&gt;&lt;font style="POSITION: relative; FONT-SIZE: 6.5pt; TOP: -3pt;" size="1"&gt;&amp;#174;&lt;/font&gt;&lt;font style="FONT-SIZE: 10pt;" size="2"&gt;&amp;#160;and VI monotherapy).&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: -0.25in; MARGIN: 0in 0in 0pt 0.5in;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;In addition, in connection with the Spin-Off, we were capitalized with $393.0 million in cash.&amp;#160; Except as expressly set forth in the Separation and Distribution Agreement or any ancillary agreement, all assets were transferred to us on an &amp;#8220;as is,&amp;#8221; &amp;#8220;where is&amp;#8221; basis.&amp;#160; Under the terms of the Separation and Distribution Agreement, we will indemnify Theravance, and Theravance will indemnify us from and after the Spin-Off with respect to all debts, liabilities and obligations transferred to Theravance in connection with the Spin-Off (including failure to pay, perform or otherwise promptly discharge any such debts, liabilities or obligations after the Spin-Off) and any breach by us of the Separation and Distribution Agreement, the Transition Services Agreement, the Employee Matters Agreement and the Tax Matters Agreement.&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;b&gt;&lt;i&gt;&lt;font style="FONT-STYLE: italic; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2"&gt;Transition Services Agreement&lt;/font&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;On June&amp;#160;2, 2014, we also entered into a Transition Services Agreement with Theravance pursuant to which Theravance and we will provide each other with a variety of administrative services, including financial, tax, accounting, information technology, legal and human resources services, for a period of time of up to two years following the Spin-Off.&amp;#160; We expect that most of these services will be provided within the first six to twelve months following the Spin-Off.&amp;#160; In connection with the services performed under the Transition Services Agreement, each party shall pay a monthly fee to the performing party.&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;b&gt;&lt;i&gt;&lt;font style="FONT-STYLE: italic; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2"&gt;Tax Matters Agreement&lt;/font&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;On June&amp;#160;2, 2014, we also entered into a Tax Matters Agreement with Theravance that governs Theravance&amp;#8217;s and our respective rights, responsibilities and obligations after the Spin-Off with respect to taxes.&amp;#160; Under the Tax Matters Agreement, all tax liabilities (including tax refunds and credits) (i)&amp;#160;attributable to Theravance&amp;#8217;s drug discovery and development business for any and all periods or portions thereof ending prior to or on, the distribution date, (ii)&amp;#160;resulting or arising from the contribution of Theravance&amp;#8217;s drug discovery and development business to us, the distribution of our ordinary shares and the other separation transactions and (iii)&amp;#160;otherwise attributable to Theravance, will be borne solely by Theravance. As a result, we should generally expect to be liable only for tax liabilities attributable to, or incurred with respect to, the drug discovery and development business after the distribution date.&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;b&gt;&lt;i&gt;&lt;font style="FONT-STYLE: italic; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2"&gt;Employee Matters Agreement&lt;/font&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;On June&amp;#160;1, 2014, we also entered into an Employee Matters Agreement with Theravance, which governs the employee benefit obligations of Theravance and us as they relate to current and former employees. The Employee Matters Agreement allocates liabilities and responsibilities relating to employee benefit matters, including 401(k)&amp;#160;plan matters that are subject to ERISA in connection with the separation, as well as other employee benefit programs. The Employee Matters Agreement also provides the mechanics for the adjustment on the distribution date of equity awards (including stock options, restricted stock, and restricted stock units) granted under Theravance&amp;#8217;s equity compensation programs.&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;b&gt;&lt;i&gt;&lt;font style="FONT-STYLE: italic; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2"&gt;Theravance Respiratory Company, LLC Limited Liability Company Agreement&lt;/font&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Prior to the Spin-Off, Theravance assigned to Theravance Respiratory Company, LLC (&amp;#8220;TRC&amp;#8221;), a Delaware limited liability company formed by Theravance, its strategic alliance agreement with GSK and all of its rights and obligations under its collaboration agreement with GSK other than with respect to RELVAR&lt;/font&gt;&lt;font style="POSITION: relative; FONT-SIZE: 6.5pt; TOP: -3pt;" size="1"&gt;&amp;#174;&lt;/font&gt;&lt;font style="FONT-SIZE: 10pt;" size="2"&gt;&amp;#160;ELLIPTA&lt;/font&gt;&lt;font style="POSITION: relative; FONT-SIZE: 6.5pt; TOP: -3pt;" size="1"&gt;&amp;#174;&lt;/font&gt;&lt;font style="FONT-SIZE: 10pt;" size="2"&gt;/BREO&lt;/font&gt;&lt;font style="POSITION: relative; FONT-SIZE: 6.5pt; TOP: -3pt;" size="1"&gt;&amp;#174;&lt;/font&gt;&lt;font style="FONT-SIZE: 10pt;" size="2"&gt;&amp;#160;ELLIPTA&lt;/font&gt;&lt;font style="POSITION: relative; FONT-SIZE: 6.5pt; TOP: -3pt;" size="1"&gt;&amp;#174;&lt;/font&gt;&lt;font style="FONT-SIZE: 10pt;" size="2"&gt;, ANORO&amp;#8482; ELLIPTA&lt;/font&gt;&lt;font style="POSITION: relative; FONT-SIZE: 6.5pt; TOP: -3pt;" size="1"&gt;&amp;#174;&lt;/font&gt;&lt;font style="FONT-SIZE: 10pt;" size="2"&gt;&amp;#160;and vilanterol monotherapy. Our equity interest in TRC entitles us to an 85% economic interest in any future payments made by GSK under the strategic alliance agreement and under the portion of the collaboration agreement assigned to TRC. The drug programs assigned to TRC include UMEC/VI/FF and the MABA program, as monotherapy and in combination with other therapeutically active components, such as an inhaled corticosteroid (ICS), and any other product or combination of products that may be discovered and developed in the future under these GSK agreements. Our economic interest will not include any payments associated with RELVAR&lt;/font&gt;&lt;font style="POSITION: relative; FONT-SIZE: 6.5pt; TOP: -3pt;" size="1"&gt;&amp;#174;&lt;/font&gt;&lt;font style="FONT-SIZE: 10pt;" size="2"&gt;&amp;#160;ELLIPTA&lt;/font&gt;&lt;font style="POSITION: relative; FONT-SIZE: 6.5pt; TOP: -3pt;" size="1"&gt;&amp;#174;&lt;/font&gt;&lt;font style="FONT-SIZE: 10pt;" size="2"&gt;/BREO&lt;/font&gt;&lt;font style="POSITION: relative; FONT-SIZE: 6.5pt; TOP: -3pt;" size="1"&gt;&amp;#174;&lt;/font&gt;&lt;font style="FONT-SIZE: 10pt;" size="2"&gt;&amp;#160;ELLIPTA&lt;/font&gt;&lt;font style="POSITION: relative; FONT-SIZE: 6.5pt; TOP: -3pt;" size="1"&gt;&amp;#174;&lt;/font&gt;&lt;font style="FONT-SIZE: 10pt;" size="2"&gt;, ANORO&amp;#8482; ELLIPTA&lt;/font&gt;&lt;font style="POSITION: relative; FONT-SIZE: 6.5pt; TOP: -3pt;" size="1"&gt;&amp;#174;&lt;/font&gt;&lt;font style="FONT-SIZE: 10pt;" size="2"&gt;&amp;#160;or vilanterol monotherapy.&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;On May&amp;#160;31, 2014, we entered into the TRC LLC Agreement with Theravance that governs the operation of TRC.&amp;#160; Under the TRC LLC Agreement, Theravance will be the manager of TRC, and the business and affairs of TRC shall be managed exclusively by the manager, including (i)&amp;#160;day to day management of the drug programs in accordance with the existing GSK agreements, (ii)&amp;#160;preparing an annual operating plan for TRC and (iii)&amp;#160;taking all actions necessary to ensure that the formation, structure and operation of TRC complies with applicable law and partner agreements.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
  <us-gaap:BasisOfAccountingPolicyPolicyTextBlock id="Tag41" contextRef="D2014Q1">&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;b&gt;&lt;i&gt;&lt;font style="FONT-STYLE: italic; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2"&gt;Basis of Presentation&lt;/font&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;The condensed&lt;/font&gt; &lt;font style="FONT-SIZE: 10pt;" size="2"&gt;combined financial information as of March&amp;#160;31, 2014, and for the three months ended March&amp;#160;31, 2013 and 2014 are unaudited but include all adjustments (consisting only of normal recurring adjustments), which we consider necessary for a fair presentation of the financial position at such date and of the operating results and cash flows for those periods, and have been prepared in accordance with U.S. generally accepted accounting principles (&amp;#8220;GAAP&amp;#8221;) for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for complete financial statements. The accompanying unaudited condensed combined financial statements should be read in conjunction with the audited combined financial statements and notes thereto included in the information statement filed as an exhibit to the Company&amp;#8217;s Registration Statement on Form&amp;#160;10 filed with the Securities and Exchange Commission (&amp;#8220;SEC&amp;#8221;) on May&amp;#160;7, 2014.&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;The accompanying unaudited condensed combined financial statements have been prepared using Theravance&amp;#8217;s historical cost basis of the assets and liabilities of the various activities that comprise the Drug Discovery and Development Business of Theravance and reflect the combined results of operations, financial condition and cash flows of Theravance Biopharma as a wholly-owned subsidiary of Theravance in conformity with U.S. GAAP. The various assets, liabilities, revenues and expenses associated with Theravance have been allocated to the historical condensed combined financial statements of Theravance Biopharma in a manner expected to be consistent with the Separation and Distribution Agreement. Changes in parent company deficit represent Theravance&amp;#8217;s net investment in Theravance Biopharma, after giving effect to Theravance Biopharma&amp;#8217;s net loss, parent company expense allocations, and net cash transfers to and from Theravance.&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;For purposes of preparing the unaudited condensed combined financial statements, the Drug Discovery and Development Business was derived from Theravance&amp;#8217;s historical consolidated financial statements, allocations of revenues, R&amp;amp;D expenses, and non-operating income and expenses to Theravance Biopharma were made on a specific identification basis. For purposes of allocating general and administrative expenses from Theravance&amp;#8217;s historical consolidated financial statements, costs directly related to the Drug Discovery and Development Business were allocated to Theravance Biopharma on a specific identification basis or based on the substance of the underlying effort. Theravance Biopharma&amp;#8217;s general and administrative expenses also include allocations of Theravance&amp;#8217;s general corporate overhead expenses, including finance, legal, human resources, information technology and other administrative functions. These allocations of general corporate overhead expenses were primarily based on the substance of the underlying effort or an estimated number of full-time employees that worked with the Drug Discovery and Development Business. The condensed combined balance sheets of Theravance Biopharma include assets and liabilities that were allocated to Theravance Biopharma principally on a specific identification basis.&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Management believes that the condensed combined statements of operations and comprehensive loss include a reasonable allocation of costs incurred by Theravance which benefited Theravance Biopharma. However, such expenses may not be indicative of the actual level of expense that would have been incurred by Theravance Biopharma if it had operated as an independent, publicly traded company or of the costs expected to be incurred in the future. As such, the financial information herein may not necessarily reflect the financial position, results of operations, and cash flows of Theravance Biopharma in the future or what it would have been had Theravance Biopharma been an independent, publicly traded company during the periods presented.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
  <us-gaap:ResearchAndDevelopmentExpense id="Tag42" contextRef="D2014Q1" unitRef="USD" decimals="-3">41723000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense id="Tag43" contextRef="D2013Q1" unitRef="USD" decimals="-3">25408000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:NetIncomeLoss id="Tag44" contextRef="D2014Q1" unitRef="USD" decimals="-3">-60018000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss id="Tag45" contextRef="D2013Q1" unitRef="USD" decimals="-3">-32174000</us-gaap:NetIncomeLoss>
  <dei:EntityRegistrantName id="Tag46" contextRef="D2014Q1">Theravance Biopharma, Inc.</dei:EntityRegistrantName>
  <dei:EntityCentralIndexKey id="Tag47" contextRef="D2014Q1">0001583107</dei:EntityCentralIndexKey>
  <dei:DocumentType id="Tag48" contextRef="D2014Q1">10-Q</dei:DocumentType>
  <dei:AmendmentFlag id="Tag49" contextRef="D2014Q1">false</dei:AmendmentFlag>
  <dei:CurrentFiscalYearEndDate id="Tag50" contextRef="D2014Q1">--12-31</dei:CurrentFiscalYearEndDate>
  <dei:EntityCurrentReportingStatus id="Tag51" contextRef="D2014Q1">No</dei:EntityCurrentReportingStatus>
  <dei:EntityFilerCategory id="Tag52" contextRef="D2014Q1">Non-accelerated Filer</dei:EntityFilerCategory>
  <dei:DocumentFiscalYearFocus id="Tag53" contextRef="D2014Q1">2014</dei:DocumentFiscalYearFocus>
  <dei:DocumentFiscalPeriodFocus id="Tag54" contextRef="D2014Q1">Q1</dei:DocumentFiscalPeriodFocus>
  <dei:DocumentPeriodEndDate id="Tag55" contextRef="D2014Q1">2014-03-31</dei:DocumentPeriodEndDate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue id="Tag56" contextRef="D2014Q1_TheravanceIncMember_EmployeeStockOptionMember" unitRef="USDPerShare" decimals="2">21.29</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:DepreciationDepletionAndAmortization id="Tag57" contextRef="D2014Q1" unitRef="USD" decimals="-3">732000</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:DepreciationDepletionAndAmortization id="Tag58" contextRef="D2013Q1" unitRef="USD" decimals="-3">703000</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:ShareBasedCompensation id="Tag59" contextRef="D2014Q1" unitRef="USD" decimals="-3">12701000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation id="Tag60" contextRef="D2013Q1" unitRef="USD" decimals="-3">5516000</us-gaap:ShareBasedCompensation>
  <us-gaap:IncreaseDecreaseInAccountsReceivable id="Tag61" contextRef="D2014Q1" unitRef="USD" decimals="-3">-196000</us-gaap:IncreaseDecreaseInAccountsReceivable>
  <us-gaap:InventoryPolicyTextBlock id="Tag62" contextRef="D2014Q1">&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;b&gt;&lt;i&gt;&lt;font style="FONT-STYLE: italic; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2"&gt;Inventories&lt;/font&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Inventories consist of raw materials, work-in-process and finished goods related to the production of VIBATIV&lt;/font&gt;&lt;font style="POSITION: relative; FONT-SIZE: 6.5pt; TOP: -3pt;" size="1"&gt;&amp;#174;&lt;/font&gt;&lt;font style="FONT-SIZE: 10pt;" size="2"&gt;&amp;#160;(telavancin). Raw materials include VIBATIV&lt;/font&gt;&lt;font style="POSITION: relative; FONT-SIZE: 6.5pt; TOP: -3pt;" size="1"&gt;&amp;#174;&lt;/font&gt;&lt;font style="FONT-SIZE: 10pt;" size="2"&gt;&amp;#160;active pharmaceutical ingredient (&amp;#8220;API&amp;#8221;) and other raw materials. Work-in-process and finished goods include third party manufacturing costs and labor and indirect costs we incur in the production process. Included in inventories are raw materials and work-in-process that may be used as clinical products, which are charged to R&amp;amp;D expense when consumed. In addition, under certain commercialization agreements, we may sell VIBATIV&lt;/font&gt;&lt;font style="POSITION: relative; FONT-SIZE: 6.5pt; TOP: -3pt;" size="1"&gt;&amp;#174;&lt;/font&gt;&lt;font style="FONT-SIZE: 10pt;" size="2"&gt;&amp;#160;packaged in unlabeled vials that are recorded in work-in-process. Inventories are stated at the lower of cost or market value. We determine the cost of inventory using the average-cost method for validation batches. We analyze our inventory levels quarterly and write down any inventory that is expected to become obsolete, that has a cost basis in excess of its expected net realizable value or for inventory quantities in excess of expected requirements.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;</us-gaap:InventoryPolicyTextBlock>
  <us-gaap:IncreaseDecreaseInAccruedLiabilities id="Tag63" contextRef="D2014Q1" unitRef="USD" decimals="-3">4563000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInAccruedLiabilities id="Tag64" contextRef="D2013Q1" unitRef="USD" decimals="-3">-3694000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInInventories id="Tag65" contextRef="D2014Q1" unitRef="USD" decimals="-3">617000</us-gaap:IncreaseDecreaseInInventories>
  <us-gaap:IncreaseDecreaseInInventories id="Tag66" contextRef="D2013Q1" unitRef="USD" decimals="-3">2481000</us-gaap:IncreaseDecreaseInInventories>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets id="Tag67" contextRef="D2014Q1" unitRef="USD" decimals="-3">1811000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets id="Tag68" contextRef="D2013Q1" unitRef="USD" decimals="-3">1255000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncreaseDecreaseInAccountsPayable id="Tag69" contextRef="D2014Q1" unitRef="USD" decimals="-3">-1094000</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:IncreaseDecreaseInAccountsPayable id="Tag70" contextRef="D2013Q1" unitRef="USD" decimals="-3">-150000</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:IncreaseDecreaseInDeferredCharges id="Tag71" contextRef="D2014Q1" unitRef="USD" decimals="-3">-117000</us-gaap:IncreaseDecreaseInDeferredCharges>
  <us-gaap:IncreaseDecreaseInDeferredCharges id="Tag72" contextRef="D2013Q1" unitRef="USD" decimals="-3">202000</us-gaap:IncreaseDecreaseInDeferredCharges>
  <us-gaap:RevenueRecognitionPolicyTextBlock id="Tag73" contextRef="D2014Q1">&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;b&gt;&lt;i&gt;&lt;font style="FONT-STYLE: italic; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2"&gt;Revenue Recognition&lt;/font&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Revenue is recognized when the four basic criteria of revenue recognition are met: (1)&amp;#160;persuasive evidence of an arrangement exists; (2)&amp;#160;delivery has occurred or services have been rendered; (3)&amp;#160;the fee is fixed or determinable; and (4)&amp;#160;collectability is reasonably assured. Determination of criteria (3)&amp;#160;and (4)&amp;#160;are based on management&amp;#8217;s judgments regarding the nature of the fee charged for products or services delivered and the collectability of those fees. Where the revenue recognition criteria are not met, we defer the recognition of revenue by recording deferred revenue until such time that all criteria are met.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
  <us-gaap:ProceedsFromSaleAndCollectionOfNotesReceivable id="Tag74" contextRef="D2013Q1" unitRef="USD" decimals="-3">100000</us-gaap:ProceedsFromSaleAndCollectionOfNotesReceivable>
  <us-gaap:IncreaseDecreaseInDeferredRevenue id="Tag75" contextRef="D2014Q1" unitRef="USD" decimals="-3">-412000</us-gaap:IncreaseDecreaseInDeferredRevenue>
  <us-gaap:IncreaseDecreaseInDeferredRevenue id="Tag76" contextRef="D2013Q1" unitRef="USD" decimals="-3">6268000</us-gaap:IncreaseDecreaseInDeferredRevenue>
  <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations id="Tag77" contextRef="D2014Q1" unitRef="USD" decimals="-3">-44799000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations id="Tag78" contextRef="D2013Q1" unitRef="USD" decimals="-3">-28491000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment id="Tag79" contextRef="D2014Q1" unitRef="USD" decimals="-3">1620000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment id="Tag80" contextRef="D2013Q1" unitRef="USD" decimals="-3">740000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:NetCashProvidedByUsedInContinuingOperations id="Tag81" contextRef="D2014Q1" unitRef="USD" decimals="-3">0</us-gaap:NetCashProvidedByUsedInContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInContinuingOperations id="Tag82" contextRef="D2013Q1" unitRef="USD" decimals="-3">0</us-gaap:NetCashProvidedByUsedInContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations id="Tag83" contextRef="D2014Q1" unitRef="USD" decimals="-3">-1620000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations id="Tag84" contextRef="D2013Q1" unitRef="USD" decimals="-3">-640000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
  <us-gaap:ProceedsFromContributionsFromParent id="Tag85" contextRef="D2014Q1" unitRef="USD" decimals="-3">46419000</us-gaap:ProceedsFromContributionsFromParent>
  <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations id="Tag86" contextRef="D2014Q1" unitRef="USD" decimals="-3">46419000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
  <us-gaap:ProceedsFromContributionsFromParent id="Tag87" contextRef="D2013Q1" unitRef="USD" decimals="-3">29131000</us-gaap:ProceedsFromContributionsFromParent>
  <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations id="Tag88" contextRef="D2013Q1" unitRef="USD" decimals="-3">29131000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="Tag89" contextRef="I2013" unitRef="USD" decimals="-3">0</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="Tag90" contextRef="I2012" unitRef="USD" decimals="-3">0</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="Tag91" contextRef="I2014Q1" unitRef="USD" decimals="-3">0</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="Tag92" contextRef="I2013Q1" unitRef="USD" decimals="-3">0</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:SellingGeneralAndAdministrativeExpense id="Tag93" contextRef="D2014Q1" unitRef="USD" decimals="-3">19052000</us-gaap:SellingGeneralAndAdministrativeExpense>
  <us-gaap:SellingGeneralAndAdministrativeExpense id="Tag94" contextRef="D2013Q1" unitRef="USD" decimals="-3">6788000</us-gaap:SellingGeneralAndAdministrativeExpense>
  <tbph:CollaborativeArrangementRevenueRecognitionTableTextBlock id="Tag95" contextRef="D2014Q1">&lt;div style="font-size:10.0pt;font-family:Times New Roman;FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;"&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="text-align:left;TEXT-ALIGN: left; WIDTH: 752px; BORDER-COLLAPSE: collapse;" border="0" cellspacing="0" cellpadding="0" width="752"&gt;

&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 68.96%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="68%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.58%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 27.42%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="27%" colspan="5"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;Three&amp;#160;Months&amp;#160;Ended&amp;#160;March&amp;#160;31,&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.04%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 68.96%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="68%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;(In&amp;#160;thousands)&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.58%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.42%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;2014&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.58%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.42%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;2013&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.04%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 68.96%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="68%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Merck&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.58%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="11%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.58%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="11%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;5&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.04%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 68.96%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="68%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;R-Pharm CJSC&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.58%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.42%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.58%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.42%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;17&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.04%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 68.96%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="68%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Total revenue from collaborative arrangements&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.58%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="11%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.58%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="11%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;22&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.04%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</tbph:CollaborativeArrangementRevenueRecognitionTableTextBlock>
  <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock id="Tag96" contextRef="D2014Q1">&lt;div style="font-size:10.0pt;font-family:Times New Roman;FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;"&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="text-align:left;TEXT-ALIGN: left; WIDTH: 758px; BORDER-COLLAPSE: collapse;" border="0" cellspacing="0" cellpadding="0" width="758"&gt;

&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 68.96%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="68%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.58%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 27.42%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="27%" colspan="5"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;Three&amp;#160;Months&amp;#160;Ended&amp;#160;March&amp;#160;31,&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.04%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 68.96%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="68%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;(In&amp;#160;thousands)&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.58%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.42%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;2014&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.58%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.42%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;2013&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.04%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 68.96%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="68%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Merck&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.58%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.34%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.08%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="11%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.58%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.34%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.08%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="11%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;1,429&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.04%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 68.96%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="68%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Alfa Wassermann societ&amp;#224; per azioni&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.58%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.42%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;72&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.58%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.42%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;208&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.04%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 68.96%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="68%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;R-Pharm CJSC&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.58%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.42%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;18&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.58%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.42%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;326&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.04%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 68.96%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="68%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Total reduction to R&amp;amp;D expense&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.58%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.34%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.08%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="11%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;90&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.58%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.34%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.08%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="11%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;1,963&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.04%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock>
  <tbph:CollaborativeArrangementsRevenue id="Tag97" contextRef="D2014Q1_MerckMember" unitRef="USD" decimals="-3">0</tbph:CollaborativeArrangementsRevenue>
  <tbph:CollaborativeArrangementsRevenue id="Tag98" contextRef="D2014Q1_RPharmCJSCMember" unitRef="USD" decimals="-3">0</tbph:CollaborativeArrangementsRevenue>
  <us-gaap:CollaborativeArrangementAccountingPolicy id="Tag99" contextRef="D2014Q1">&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;i&gt;&lt;font style="FONT-STYLE: italic; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Collaborative Arrangements and Multiple-Element Arrangements&lt;/font&gt;&lt;/i&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Revenue from nonrefundable, up-front license or technology access payments under license and collaborative arrangements that are not dependent on any future performance by us is recognized when such amounts are earned. If we have continuing obligations to perform under the arrangement, such fees are recognized over the estimated period of continuing performance obligation.&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;We account for multiple element arrangements, such as license and development agreements in which a customer may purchase several deliverables, in accordance with Financial Accounting Standards Board (&amp;#8220;FASB&amp;#8221;) Accounting Standards Codification (&amp;#8220;ASC&amp;#8221;) Subtopic 605-25, &amp;#8220;Multiple Element Arrangements.&amp;#8221; For new or materially amended multiple element arrangements, we identify the deliverables at the inception of the arrangement and each deliverable within a multiple deliverable revenue arrangement is accounted for as a separate unit of accounting if both of the following criteria are met: (1)&amp;#160;the delivered item or items have value to the customer on a standalone basis and (2)&amp;#160;for an arrangement that includes a general right of return relative to the delivered item(s), delivery or performance of the undelivered item(s)&amp;#160;is considered probable and substantially in our control. We allocate revenue to each non-contingent element based on the relative selling price of each element. When applying the relative selling price method, we determine the selling price for each deliverable using vendor-specific objective evidence (&amp;#8220;VSOE&amp;#8221;) of selling price, if it exists, or third-party evidence (&amp;#8220;TPE&amp;#8221;) of selling price, if it exists. If neither VSOE nor TPE of selling price exist for a deliverable, we use the best estimated selling price for that deliverable. Revenue allocated to each element is then recognized based on when the basic four revenue recognition criteria are met for each element.&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;For multiple-element arrangements entered into prior to January&amp;#160;1, 2011, we determined the delivered items under our collaborative arrangements did not meet the criteria to be considered separate accounting units for the purposes of revenue recognition. As a result, we recognized revenue from non-refundable, upfront fees and development contingent payments in the same manner as the final deliverable, which is ratably over the expected term of our performance of R&amp;amp;D services under the agreements. These upfront or contingent payments received, pending recognition as revenue, are recorded as deferred revenue and are classified as a current or non-current liability on the consolidated balance sheets and recognized over the estimated period of performance. We periodically review the estimated performance periods of our contracts based on the progress of our programs.&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Where a portion of non-refundable upfront fees or other payments received are allocated to continuing performance obligations under the terms of a collaborative arrangement, they are recorded as deferred revenue and recognized as revenue or as an accrued liability and recognized as a reduction of R&amp;amp;D expenses ratably over the term of our estimated performance period under the agreement. We determine the estimated performance periods, and they are periodically reviewed based on the progress of the related program. The effect of any change made to an estimated performance period and, therefore revenue recognized, would occur on a prospective basis in the period that the change was made.&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Under certain collaborative arrangements, we have been reimbursed for a portion of our R&amp;amp;D expenses. These reimbursements have been reflected as a reduction of R&amp;amp;D expense in our consolidated statements of operations, as we do not consider performing research and development services to be a part of our ongoing and central operations. Therefore, the reimbursement of research and developmental services and any amounts allocated to our research and development services are recorded as a reduction of R&amp;amp;D expense.&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Amounts deferred under a collaborative arrangement in which the performance obligations are terminated will result in an immediate recognition of any remaining deferred revenue and accrued liability in the period that termination occurred, provided that there are no remaining performance obligations.&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;We account for contingent payments in accordance with FASB Subtopic ASC 605-28 &amp;#8220;Revenue Recognition&amp;#8212;Milestone Method.&amp;#8221; We recognize revenue from milestone payments when (i)&amp;#160;the milestone event is substantive and its achievability was not reasonably assured at the inception of the agreement and (ii)&amp;#160;we do not have ongoing performance obligations related to the achievement of the milestone. Milestone payments are considered substantive if all of the following conditions are met: the milestone payment (a)&amp;#160;is commensurate with either our performance to achieve the milestone or the enhancement of the value of the delivered item or items as a result of a specific outcome resulting from our performance to achieve the milestone, (b)&amp;#160;relates solely to past performance, and (c)&amp;#160;is reasonable relative to all of the deliverables and payment terms (including other potential milestone consideration) within the arrangement.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;</us-gaap:CollaborativeArrangementAccountingPolicy>
  <tbph:CollaborativeArrangementsRevenue id="Tag100" contextRef="D2013Q1_MerckMember" unitRef="USD" decimals="-3">5000</tbph:CollaborativeArrangementsRevenue>
  <tbph:CollaborativeArrangementsRevenue id="Tag101" contextRef="D2013Q1_RPharmCJSCMember" unitRef="USD" decimals="-3">17000</tbph:CollaborativeArrangementsRevenue>
  <tbph:CollaborativeArrangementsRevenue id="Tag102" contextRef="D2013Q1" unitRef="USD" decimals="-3">22000</tbph:CollaborativeArrangementsRevenue>
  <tbph:CollaborativeArrangementResearchAndDevelopmentExpensesReimbursedToEntity id="Tag103" contextRef="D2014Q1_MerckMember" unitRef="USD" decimals="-3">0</tbph:CollaborativeArrangementResearchAndDevelopmentExpensesReimbursedToEntity>
  <tbph:CollaborativeArrangementResearchAndDevelopmentExpensesReimbursedToEntity id="Tag104" contextRef="D2014Q1_AlfaWassermannMember" unitRef="USD" decimals="-3">72000</tbph:CollaborativeArrangementResearchAndDevelopmentExpensesReimbursedToEntity>
  <tbph:CollaborativeArrangementResearchAndDevelopmentExpensesReimbursedToEntity id="Tag105" contextRef="D2014Q1_RPharmCJSCMember" unitRef="USD" decimals="-3">18000</tbph:CollaborativeArrangementResearchAndDevelopmentExpensesReimbursedToEntity>
  <tbph:CollaborativeArrangementResearchAndDevelopmentExpensesReimbursedToEntity id="Tag106" contextRef="D2014Q1" unitRef="USD" decimals="-3">90000</tbph:CollaborativeArrangementResearchAndDevelopmentExpensesReimbursedToEntity>
  <tbph:CollaborativeArrangementResearchAndDevelopmentExpensesReimbursedToEntity id="Tag107" contextRef="D2013Q1_MerckMember" unitRef="USD" decimals="-3">1429000</tbph:CollaborativeArrangementResearchAndDevelopmentExpensesReimbursedToEntity>
  <tbph:CollaborativeArrangementResearchAndDevelopmentExpensesReimbursedToEntity id="Tag108" contextRef="D2013Q1_AlfaWassermannMember" unitRef="USD" decimals="-3">208000</tbph:CollaborativeArrangementResearchAndDevelopmentExpensesReimbursedToEntity>
  <tbph:CollaborativeArrangementResearchAndDevelopmentExpensesReimbursedToEntity id="Tag109" contextRef="D2013Q1_RPharmCJSCMember" unitRef="USD" decimals="-3">326000</tbph:CollaborativeArrangementResearchAndDevelopmentExpensesReimbursedToEntity>
  <tbph:CollaborativeArrangementResearchAndDevelopmentExpensesReimbursedToEntity id="Tag110" contextRef="D2013Q1" unitRef="USD" decimals="-3">1963000</tbph:CollaborativeArrangementResearchAndDevelopmentExpensesReimbursedToEntity>
  <tbph:CollaborativeArrangementUpfrontPaymentsReceived id="Tag111" contextRef="D2013Q1_M03_ClinigenMember_CommercializationAgreementMember_TheravanceIncMember_VIBATIVMember" unitRef="USD" decimals="-5">5000000</tbph:CollaborativeArrangementUpfrontPaymentsReceived>
  <us-gaap:RevenueRecognitionAccountingPolicyGrossAndNetRevenueDisclosure id="Tag112" contextRef="D2014Q1">&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;i&gt;&lt;font style="FONT-STYLE: italic; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Product Revenues&lt;/font&gt;&lt;/i&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;We sell VIBATIV&lt;/font&gt;&lt;font style="POSITION: relative; FONT-SIZE: 6.5pt; TOP: -3pt;" size="1"&gt;&amp;#174;&lt;/font&gt;&lt;font style="FONT-SIZE: 10pt;" size="2"&gt;&amp;#160;in the U.S. through a limited number of distributors, and title and risk of loss transfer upon receipt by these distributors. Healthcare providers order VIBATIV&lt;/font&gt;&lt;font style="POSITION: relative; FONT-SIZE: 6.5pt; TOP: -3pt;" size="1"&gt;&amp;#174;&lt;/font&gt;&lt;font style="FONT-SIZE: 10pt;" size="2"&gt;&amp;#160;through these distributors. Commencing in the first quarter of 2014, we record revenue on the sale of VIBATIV&lt;/font&gt;&lt;font style="POSITION: relative; FONT-SIZE: 6.5pt; TOP: -3pt;" size="1"&gt;&amp;#174;&lt;/font&gt; &lt;font style="FONT-SIZE: 10pt;" size="2"&gt;on a sell-through basis, once the distributors sell the product to healthcare providers.&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Product sales are recorded net of estimated government-mandated rebates and chargebacks, distribution fees, estimated product returns and other deductions. We reflect such reductions in revenue as either an allowance to the related account receivable from the distributor, or as an accrued liability, depending on the nature of the sales deduction. Sales deductions are based on management&amp;#8217;s estimates that consider payer mix in target markets, industry benchmarks and experience to date. We monitor inventory levels in the distribution channel, as well as sales of VIBATIV&lt;/font&gt;&lt;font style="POSITION: relative; FONT-SIZE: 6.5pt; TOP: -3pt;" size="1"&gt;&amp;#174;&lt;/font&gt;&lt;font style="FONT-SIZE: 10pt;" size="2"&gt;&amp;#160;by distributors to healthcare providers, using product-specific data provided by the distributors. Product return allowances are based on amounts owed or to be claimed on related sales. These estimates take into consideration the terms of our agreements with customers, historical product returns of VIBATIV&lt;/font&gt;&lt;font style="POSITION: relative; FONT-SIZE: 6.5pt; TOP: -3pt;" size="1"&gt;&amp;#174;&lt;/font&gt;&lt;font style="FONT-SIZE: 10pt;" size="2"&gt;&amp;#160;experienced by Theravance&amp;#8217;s former collaborative partner, Astellas, rebates or discounts taken, estimated levels of inventory in the distribution channel, the shelf life of the product, and specific known market events, such as competitive pricing and new product introductions. We update our estimates and assumptions each quarter and if actual future results vary from our estimates, we may adjust these estimates, which could have an effect on product sales and earnings in the period of adjustment.&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;i&gt;&lt;u&gt;&lt;font style="FONT-STYLE: italic; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Sales Discounts:&lt;/font&gt;&lt;/u&gt;&lt;/i&gt;&lt;font style="FONT-SIZE: 10pt;" size="2"&gt;&amp;#160; We offer cash discounts to our customers, generally 2% of the sales price, as an incentive for prompt payment. We expect our customers to comply with the prompt payment terms to earn the cash discount. We account for cash discounts by reducing accounts receivable by the full amount and recognizing the discount as a reduction of revenue in the same period the related revenue is recognized.&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;i&gt;&lt;u&gt;&lt;font style="FONT-STYLE: italic; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Chargebacks and Government Rebates:&lt;/font&gt;&lt;/u&gt;&lt;/i&gt;&lt;font style="FONT-SIZE: 10pt;" size="2"&gt;&amp;#160; For VIBATIV&lt;/font&gt;&lt;font style="POSITION: relative; FONT-SIZE: 6.5pt; TOP: -3pt;" size="1"&gt;&amp;#174;&lt;/font&gt;&lt;font style="FONT-SIZE: 10pt;" size="2"&gt;&amp;#160;sales in the U.S., we estimate reductions to product sales for qualifying federal and state government programs including discounted pricing offered to Public Health Service (PHS) as well as government-managed Medicaid programs. Our reduction for PHS is based on actual chargebacks that distributors have claimed for reduced pricing offered to such health care providers. Our accrual for Medicaid is based upon statutorily-defined discounts, estimated payer mix, expected sales to qualified healthcare providers, and our expectation about future utilization. The Medicaid accrual and government rebates that are invoiced directly to us are recorded in other accrued liabilities on the consolidated balance sheet. For qualified programs that can purchase our products through distributors at a lower contractual government price, the distributors charge back to us the difference between their acquisition cost and the lower contractual government price, which we record as an allowance against accounts receivable.&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;i&gt;&lt;u&gt;&lt;font style="FONT-STYLE: italic; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Distribution Fees and Product Returns:&lt;/font&gt;&lt;/u&gt;&lt;/i&gt;&lt;font style="FONT-SIZE: 10pt;" size="2"&gt;&amp;#160; We have written contracts with our distributors that include terms for distribution-related fees. We record distribution-related fees based on a percentage of the product sales price. We offer our distributors a right to return product purchased directly from us, which is principally based upon the product&amp;#8217;s expiration date. Additionally, we have granted more expansive return rights to our distributors following our product launch of VIBATIV&lt;/font&gt;&lt;font style="POSITION: relative; FONT-SIZE: 6.5pt; TOP: -3pt;" size="1"&gt;&amp;#174;&lt;/font&gt;&lt;font style="FONT-SIZE: 10pt;" size="2"&gt;. We will generally accept product returns during the six months prior to and twelve months after the product expiration date on product that had been sold to our distributors. Product returned is generally not resalable given the nature of our products and method of administration. We have developed estimates for VIBATIV&lt;/font&gt;&lt;font style="POSITION: relative; FONT-SIZE: 6.5pt; TOP: -3pt;" size="1"&gt;&amp;#174;&lt;/font&gt;&lt;font style="FONT-SIZE: 10pt;" size="2"&gt;&amp;#160;product returns based upon historical VIBATIV&lt;/font&gt;&lt;font style="POSITION: relative; FONT-SIZE: 6.5pt; TOP: -3pt;" size="1"&gt;&amp;#174;&lt;/font&gt;&lt;font style="FONT-SIZE: 10pt;" size="2"&gt;&amp;#160;sales from Theravance&amp;#8217;s former collaborative partner, Astellas. We record distribution fees and product returns as an allowance against accounts receivable.&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;i&gt;&lt;u&gt;&lt;font style="FONT-STYLE: italic; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Allowance for Doubtful Accounts:&lt;/font&gt;&lt;/u&gt;&lt;/i&gt;&lt;font style="FONT-SIZE: 10pt;" size="2"&gt;&amp;#160; We maintain a policy to record allowances for potentially doubtful accounts for estimated losses resulting from the inability of our customers to make required payments. As of March&amp;#160;31, 2014 and December&amp;#160;31, 2013, there was no allowance for doubtful accounts as we have not had any write-offs historically.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;</us-gaap:RevenueRecognitionAccountingPolicyGrossAndNetRevenueDisclosure>
  <tbph:CollaborativeArrangementUpfrontFeesReceivedAllocatedToLicense id="Tag113" contextRef="D2013Q1_M03_ClinigenMember_CommercializationAgreementMember_TheravanceIncMember_VIBATIVMember" unitRef="USD" decimals="-5">4900000</tbph:CollaborativeArrangementUpfrontFeesReceivedAllocatedToLicense>
  <tbph:CollaborativeArrangementUpfrontFeesReceivedAllocatedToCommitteeServices id="Tag114" contextRef="D2013Q1_M03_ClinigenMember_CommercializationAgreementMember_TheravanceIncMember_VIBATIVMember" unitRef="USD" decimals="-5">100000</tbph:CollaborativeArrangementUpfrontFeesReceivedAllocatedToCommitteeServices>
  <tbph:CollaborativeArrangementAnnualRoyaltiesAsPercentageOfNetSales id="Tag115" contextRef="D2013Q1_M03_ClinigenMember_CommercializationAgreementMember_TheravanceIncMember_MinimumMember_VIBATIVMember" unitRef="Pure" decimals="2">0.20</tbph:CollaborativeArrangementAnnualRoyaltiesAsPercentageOfNetSales>
  <tbph:CollaborativeArrangementAnnualRoyaltiesAsPercentageOfNetSales id="Tag116" contextRef="D2013Q1_M03_CommercializationAgreementMember_ClinigenMember_TheravanceIncMember_MaximumMember_VIBATIVMember" unitRef="Pure" decimals="2">0.30</tbph:CollaborativeArrangementAnnualRoyaltiesAsPercentageOfNetSales>
  <tbph:CollaborativeAgreementTerminationTerm id="Tag117" contextRef="D2013Q1_M03_ClinigenMember_CommercializationAgreementMember_TheravanceIncMember_MinimumMember_VIBATIVMember">P15Y</tbph:CollaborativeAgreementTerminationTerm>
  <tbph:CollaborativeAgreementTerminationAdvanceNoticeTerm id="Tag118" contextRef="D2013Q1_M03_ClinigenMember_CommercializationAgreementMember_TheravanceIncMember_VIBATIVMember">P12M</tbph:CollaborativeAgreementTerminationAdvanceNoticeTerm>
  <us-gaap:ScheduleOfInventoryCurrentTableTextBlock id="Tag119" contextRef="D2014Q1">&lt;div style="font-size:10.0pt;font-family:Times New Roman;FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="text-align:left;TEXT-ALIGN: left; WIDTH: 752px; BORDER-COLLAPSE: collapse;" border="0" cellspacing="0" cellpadding="0" width="752"&gt;

&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 68.96%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="68%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.58%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.42%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;March&amp;#160;31,&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.58%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.42%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;December&amp;#160;31,&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.04%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 68.96%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="68%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;(In&amp;#160;thousands)&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.58%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.42%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;2014&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.58%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.42%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;2013&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.04%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 68.96%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="68%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Raw materials&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.58%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.34%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.08%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="11%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;3,997&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.58%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.34%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.08%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="11%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;5,138&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.04%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 68.96%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="68%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Work-in-process&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.58%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.42%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;2,225&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.58%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.42%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;360&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.04%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 68.96%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="68%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Finished goods&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.58%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.42%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;4,792&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.58%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.42%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;4,908&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.04%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 68.96%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="68%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Total inventories&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.58%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.34%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.08%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="11%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;11,014&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.58%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.34%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.08%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="11%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;10,406&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.04%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
  <us-gaap:InventoryNet id="Tag120" contextRef="I2014Q1" unitRef="USD" decimals="-3">11014000</us-gaap:InventoryNet>
  <us-gaap:InventoryNet id="Tag121" contextRef="I2013" unitRef="USD" decimals="-3">10406000</us-gaap:InventoryNet>
  <tbph:CashSalesDiscountsPercentage id="Tag122" contextRef="D2014Q1_VIBATIVProductMember" unitRef="Pure" decimals="2">0.02</tbph:CashSalesDiscountsPercentage>
  <tbph:ProductReturnAcceptancePeriodPriorToProductExpirationDate id="Tag123" contextRef="D2014Q1_VIBATIVProductMember">P6M</tbph:ProductReturnAcceptancePeriodPriorToProductExpirationDate>
  <tbph:ProductReturnAcceptancePeriodAfterProductExpirationDate id="Tag124" contextRef="D2014Q1_VIBATIVProductMember">P12M</tbph:ProductReturnAcceptancePeriodAfterProductExpirationDate>
  <us-gaap:AllowanceForDoubtfulAccountsReceivable id="Tag125" contextRef="I2014Q1" unitRef="USD" decimals="-3">0</us-gaap:AllowanceForDoubtfulAccountsReceivable>
  <tbph:LongTermRetentionProgramPeriod id="Tag126" contextRef="D2011_TheravanceIncMember_SpecialLongTermRetentionAwards2011Member">P6Y</tbph:LongTermRetentionProgramPeriod>
  <tbph:LongTermRetentionProgramCashBonusExpenseRecognized id="Tag127" contextRef="D2014Q1_TheravanceIncMember_SpecialLongTermRetentionAwards2011Member_DeferredCashBonusMember" unitRef="USD" decimals="-5">9100000</tbph:LongTermRetentionProgramCashBonusExpenseRecognized>
  <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock id="Tag128" contextRef="D2014Q1">&lt;div style="font-size:10.0pt;font-family:Times New Roman;FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;"&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="text-align:left;TEXT-ALIGN: left; WIDTH: 749px; BORDER-COLLAPSE: collapse;" border="0" cellspacing="0" cellpadding="0" width="749"&gt;

&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 68.96%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="68%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.58%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 27.42%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="27%" colspan="5"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;Three&amp;#160;Months&amp;#160;Ended&amp;#160;March&amp;#160;31,&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.04%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 68.96%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="68%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;(In&amp;#160;thousands)&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.58%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.42%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;2014&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.58%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.42%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;2013&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.04%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 68.96%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="68%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Research and development&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.58%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.34%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.08%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="11%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;4,721&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.58%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.34%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.08%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="11%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;3,688&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.04%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 68.96%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="68%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Selling, general and administrative&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.58%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.42%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;7,980&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.58%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.42%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;1,828&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.04%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 68.96%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="68%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Total stock-based compensation expense&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.58%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.34%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.08%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="11%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;12,701&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.58%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.34%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.08%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="11%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;5,516&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.04%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
  <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock id="Tag129" contextRef="D2014Q1">&lt;div style="font-size:10.0pt;font-family:Times New Roman;FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;"&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="text-align:left;TEXT-ALIGN: left; WIDTH: 828px; BORDER-COLLAPSE: collapse;" border="0" cellspacing="0" cellpadding="0" width="828"&gt;

&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 70%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="70%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 26.5%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="26%" colspan="5"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;Three&amp;#160;Months&amp;#160;Ended&lt;br /&gt;
March&amp;#160;31,&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 70%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="70%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;2014&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;2013&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 70%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="70%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;b&gt;&lt;i&gt;&lt;font style="FONT-STYLE: italic; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2"&gt;Employee stock options&lt;/font&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 70%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="70%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Risk-free interest rate&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;1.8-2.0&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;%&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;1.0%-1.1&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;%&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 70%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="70%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Expected term (in years)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;6&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;6&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 70%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="70%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Volatility&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;60&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;%&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;58&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;%&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 70%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="70%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Dividend yield&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;%&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;%&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 70%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="70%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Weighted-average estimated fair value of stock options granted&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.7%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="10%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;21.29&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.7%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="10%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;12.32&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
  <tbph:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantApprovalPeriodAsApprovedByBoardOfDirectors id="Tag130" contextRef="D2014Q1_TheravanceIncMember_RestrictedStockMember_PerformanceContingentMember">P3Y</tbph:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantApprovalPeriodAsApprovedByBoardOfDirectors>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized id="Tag131" contextRef="I2011_TheravanceIncMember_RestrictedStockMember_PerformanceContingentMember_SpecialLongTermRetentionAwards2011Member" unitRef="Shares" decimals="INF">1290000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1 id="Tag132" contextRef="D2011_TheravanceIncMember_RestrictedStockMember_PerformanceContingentMember_SpecialLongTermRetentionAwards2011Member">P6Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
  <us-gaap:AllocatedShareBasedCompensationExpense id="Tag133" contextRef="D2014Q1_TheravanceIncMember_RestrictedStockMember_PerformanceContingentMember_SpecialLongTermRetentionAwards2011Member" unitRef="USD" decimals="-5">6800000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="Tag134" contextRef="D2014Q1_ResearchAndDevelopmentExpenseMember" unitRef="USD" decimals="-3">4721000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="Tag135" contextRef="D2014Q1_SellingGeneralAndAdministrativeExpensesMember" unitRef="USD" decimals="-3">7980000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="Tag136" contextRef="D2014Q1" unitRef="USD" decimals="-3">12701000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="Tag137" contextRef="D2013Q1_ResearchAndDevelopmentExpenseMember" unitRef="USD" decimals="-3">3688000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="Tag138" contextRef="D2013Q1_SellingGeneralAndAdministrativeExpensesMember" unitRef="USD" decimals="-3">1828000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="Tag139" contextRef="D2013Q1" unitRef="USD" decimals="-3">5516000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum id="Tag140" contextRef="D2014Q1_TheravanceIncMember_EmployeeStockOptionMember" unitRef="Pure" decimals="3">0.018</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum id="Tag141" contextRef="D2013Q1_TheravanceIncMember_EmployeeStockOptionMember" unitRef="Pure" decimals="3">0.010</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum id="Tag142" contextRef="D2014Q1_TheravanceIncMember_EmployeeStockOptionMember" unitRef="Pure" decimals="3">0.020</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum id="Tag143" contextRef="D2013Q1_TheravanceIncMember_EmployeeStockOptionMember" unitRef="Pure" decimals="3">0.011</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 id="Tag144" contextRef="D2014Q1_TheravanceIncMember_EmployeeStockOptionMember">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 id="Tag145" contextRef="D2013Q1_TheravanceIncMember_EmployeeStockOptionMember">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate id="Tag146" contextRef="D2014Q1_TheravanceIncMember_EmployeeStockOptionMember" unitRef="Pure" decimals="2">0.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate id="Tag147" contextRef="D2013Q1_TheravanceIncMember_EmployeeStockOptionMember" unitRef="Pure" decimals="2">0.58</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate id="Tag148" contextRef="D2014Q1_TheravanceIncMember_EmployeeStockOptionMember" unitRef="Pure" decimals="2">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate id="Tag149" contextRef="D2013Q1_TheravanceIncMember_EmployeeStockOptionMember" unitRef="Pure" decimals="2">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue id="Tag150" contextRef="D2013Q1_TheravanceIncMember_EmployeeStockOptionMember" unitRef="USDPerShare" decimals="2">12.32</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <dei:EntityCommonStockSharesOutstanding id="Tag151" contextRef="I2014Q2SO" unitRef="Shares" decimals="INF">32260105</dei:EntityCommonStockSharesOutstanding>
  <us-gaap:AccountsReceivableNetCurrent id="Tag152" contextRef="I2014Q1" unitRef="USD" decimals="-3">3000</us-gaap:AccountsReceivableNetCurrent>
  <us-gaap:AccountsReceivableNetCurrent id="Tag153" contextRef="I2013" unitRef="USD" decimals="-3">199000</us-gaap:AccountsReceivableNetCurrent>
  <tbph:ReceivablesFromCollaborativeArrangements id="Tag154" contextRef="I2014Q1" unitRef="USD" decimals="-3">90000</tbph:ReceivablesFromCollaborativeArrangements>
  <tbph:ReceivablesFromCollaborativeArrangements id="Tag155" contextRef="I2013" unitRef="USD" decimals="-3">934000</tbph:ReceivablesFromCollaborativeArrangements>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent id="Tag156" contextRef="I2014Q1" unitRef="USD" decimals="-3">4493000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent id="Tag157" contextRef="I2013" unitRef="USD" decimals="-3">2567000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:AssetsCurrent id="Tag158" contextRef="I2014Q1" unitRef="USD" decimals="-3">15600000</us-gaap:AssetsCurrent>
  <us-gaap:AssetsCurrent id="Tag159" contextRef="I2013" unitRef="USD" decimals="-3">14106000</us-gaap:AssetsCurrent>
  <us-gaap:IncreaseDecreaseInOtherReceivables id="Tag160" contextRef="D2014Q1" unitRef="USD" decimals="-3">-844000</us-gaap:IncreaseDecreaseInOtherReceivables>
  <us-gaap:IncreaseDecreaseInOtherReceivables id="Tag161" contextRef="D2013Q1" unitRef="USD" decimals="-3">1022000</us-gaap:IncreaseDecreaseInOtherReceivables>
  <tbph:CollaborativeAgreementNumberOfUnitsOfAccountingToWhichUpfrontPaymentReceivedWasAllocated id="Tag162" contextRef="D2013Q1_M03_ClinigenMember_CommercializationAgreementMember_TheravanceIncMember_VIBATIVMember" unitRef="Item" decimals="INF">2</tbph:CollaborativeAgreementNumberOfUnitsOfAccountingToWhichUpfrontPaymentReceivedWasAllocated>
  <us-gaap:AllowanceForDoubtfulAccountsReceivable id="Tag163" contextRef="I2013" unitRef="USD" decimals="-3">0</us-gaap:AllowanceForDoubtfulAccountsReceivable>
  <us-gaap:ComprehensiveIncomeNetOfTax id="Tag164" contextRef="D2014Q1" unitRef="USD" decimals="-3">-60018000</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:ComprehensiveIncomeNetOfTax id="Tag165" contextRef="D2013Q1" unitRef="USD" decimals="-3">-32174000</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent id="Tag166" contextRef="I2014Q1" unitRef="USD" decimals="-3">209000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
  <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent id="Tag167" contextRef="I2013" unitRef="USD" decimals="-3">89000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
  <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock id="Tag168" contextRef="D2014Q1">&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2"&gt;1. Description of Operations and Summary of Significant Accounting Policies&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;b&gt;&lt;i&gt;&lt;font style="FONT-STYLE: italic; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2"&gt;Description of Operations&lt;/font&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;In April&amp;#160;2013, Theravance,&amp;#160;Inc. (&amp;#8220;Theravance&amp;#8221;) announced its intent to spin off its drug discovery and development business which is focused on discovery, development and commercialization of small-molecule medicines in areas of significant unmet medical need (&amp;#8220;Drug Discovery and Development Business&amp;#8221;) from its development and commercial responsibilities under the 2002 collaboration agreement and the 2004 strategic alliance agreement, each with Glaxo Group Limited (which we refer to, together with its affiliates, as &amp;#8220;GSK&amp;#8221;) and associated potential royalty revenues from RELVAR&lt;/font&gt;&lt;font style="POSITION: relative; FONT-SIZE: 6.5pt; TOP: -3pt;" size="1"&gt;&amp;#174;&lt;/font&gt;&lt;font style="FONT-SIZE: 10pt;" size="2"&gt;&amp;#160;ELLIPTA&lt;/font&gt;&lt;font style="POSITION: relative; FONT-SIZE: 6.5pt; TOP: -3pt;" size="1"&gt;&amp;#174;&lt;/font&gt;&lt;font style="FONT-SIZE: 10pt;" size="2"&gt;/BREO&lt;/font&gt;&lt;font style="POSITION: relative; FONT-SIZE: 6.5pt; TOP: -3pt;" size="1"&gt;&amp;#174;&lt;/font&gt;&lt;font style="FONT-SIZE: 10pt;" size="2"&gt;&amp;#160;ELLIPTA&lt;/font&gt;&lt;font style="POSITION: relative; FONT-SIZE: 6.5pt; TOP: -3pt;" size="1"&gt;&amp;#174;&lt;/font&gt;&lt;font style="FONT-SIZE: 10pt;" size="2"&gt;&amp;#160;(fluticasone furoate/vilanterol: FF/VI), ANORO&amp;#8482; ELLIPTA&lt;/font&gt;&lt;font style="POSITION: relative; FONT-SIZE: 6.5pt; TOP: -3pt;" size="1"&gt;&amp;#174;&lt;/font&gt;&lt;font style="FONT-SIZE: 10pt;" size="2"&gt;&amp;#160;(umeclidinium bromide/vilanterol: UMEC/VI) and vilanterol monotherapy. On June&amp;#160;1, 2014 Theravance transferred its research and development (&amp;#8220;R&amp;amp;D&amp;#8221;) operations to Theravance Biopharma,&amp;#160;Inc., and on June&amp;#160;2, 2014 Theravance made a pro rata dividend distribution to its stockholders of record on May&amp;#160;15, 2014 of one ordinary share of Theravance Biopharma,&amp;#160;Inc. for every three and one half shares of Theravance common stock outstanding on the record date (the &amp;#8220;Spin-Off&amp;#8221;) resulting in a dividend of 32,260,105 ordinary shares of Theravance Biopharma distributed to Theravance&amp;#8217;s stockholders.&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;The Spin-Off was effected pursuant to a Separation and Distribution Agreement between Theravance and Theravance Biopharma,&amp;#160;Inc. (the &amp;#8220;Separation and Distribution Agreement&amp;#8221;), which provides, among other things, for the principal corporate transactions required to effect the Spin-Off and certain other agreements governing Theravance&amp;#8217;s relationship with Theravance Biopharma,&amp;#160;Inc. after the Spin-Off. These agreements are discussed further in Note 7.&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Theravance Biopharma,&amp;#160;Inc. (&amp;#8220;Theravance Biopharma&amp;#8221;, the &amp;#8220;Company&amp;#8221;, or &amp;#8220;we&amp;#8221; and other similar pronouns) is a biopharmaceutical company with a pipeline of internally discovered product candidates, strategic collaborations with pharmaceutical companies and an approved product. Theravance Biopharma is focused on the discovery, development and commercialization of small molecule medicines across a number of therapeutic areas including bacterial infections, central nervous system (&amp;#8220;CNS&amp;#8221;)/pain, respiratory disease, and gastrointestinal (&amp;#8220;GI&amp;#8221;) motility dysfunction. We also have an economic interest in future payments that may be made by GSK under agreements with Theravance relating to certain drug programs, including UMEC/VI/FF and the MABA program, as monotherapy with GSK961081 (&amp;#8216;081) and as a combination (&amp;#8216;081/FF).&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;b&gt;&lt;i&gt;&lt;font style="FONT-STYLE: italic; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2"&gt;Basis of Presentation&lt;/font&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;The condensed&lt;/font&gt; &lt;font style="FONT-SIZE: 10pt;" size="2"&gt;combined financial information as of March&amp;#160;31, 2014, and for the three months ended March&amp;#160;31, 2013 and 2014 are unaudited but include all adjustments (consisting only of normal recurring adjustments), which we consider necessary for a fair presentation of the financial position at such date and of the operating results and cash flows for those periods, and have been prepared in accordance with U.S. generally accepted accounting principles (&amp;#8220;GAAP&amp;#8221;) for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for complete financial statements. The accompanying unaudited condensed combined financial statements should be read in conjunction with the audited combined financial statements and notes thereto included in the information statement filed as an exhibit to the Company&amp;#8217;s Registration Statement on Form&amp;#160;10 filed with the Securities and Exchange Commission (&amp;#8220;SEC&amp;#8221;) on May&amp;#160;7, 2014.&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;The accompanying unaudited condensed combined financial statements have been prepared using Theravance&amp;#8217;s historical cost basis of the assets and liabilities of the various activities that comprise the Drug Discovery and Development Business of Theravance and reflect the combined results of operations, financial condition and cash flows of Theravance Biopharma as a wholly-owned subsidiary of Theravance in conformity with U.S. GAAP. The various assets, liabilities, revenues and expenses associated with Theravance have been allocated to the historical condensed combined financial statements of Theravance Biopharma in a manner expected to be consistent with the Separation and Distribution Agreement. Changes in parent company deficit represent Theravance&amp;#8217;s net investment in Theravance Biopharma, after giving effect to Theravance Biopharma&amp;#8217;s net loss, parent company expense allocations, and net cash transfers to and from Theravance.&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;For purposes of preparing the unaudited condensed combined financial statements, the Drug Discovery and Development Business was derived from Theravance&amp;#8217;s historical consolidated financial statements, allocations of revenues, R&amp;amp;D expenses, and non-operating income and expenses to Theravance Biopharma were made on a specific identification basis. For purposes of allocating general and administrative expenses from Theravance&amp;#8217;s historical consolidated financial statements, costs directly related to the Drug Discovery and Development Business were allocated to Theravance Biopharma on a specific identification basis or based on the substance of the underlying effort. Theravance Biopharma&amp;#8217;s general and administrative expenses also include allocations of Theravance&amp;#8217;s general corporate overhead expenses, including finance, legal, human resources, information technology and other administrative functions. These allocations of general corporate overhead expenses were primarily based on the substance of the underlying effort or an estimated number of full-time employees that worked with the Drug Discovery and Development Business. The condensed combined balance sheets of Theravance Biopharma include assets and liabilities that were allocated to Theravance Biopharma principally on a specific identification basis.&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Management believes that the condensed combined statements of operations and comprehensive loss include a reasonable allocation of costs incurred by Theravance which benefited Theravance Biopharma. However, such expenses may not be indicative of the actual level of expense that would have been incurred by Theravance Biopharma if it had operated as an independent, publicly traded company or of the costs expected to be incurred in the future. As such, the financial information herein may not necessarily reflect the financial position, results of operations, and cash flows of Theravance Biopharma in the future or what it would have been had Theravance Biopharma been an independent, publicly traded company during the periods presented.&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;b&gt;&lt;i&gt;&lt;font style="FONT-STYLE: italic; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2"&gt;Inventories&lt;/font&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Inventories consist of raw materials, work-in-process and finished goods related to the production of VIBATIV&lt;/font&gt;&lt;font style="POSITION: relative; FONT-SIZE: 6.5pt; TOP: -3pt;" size="1"&gt;&amp;#174;&lt;/font&gt;&lt;font style="FONT-SIZE: 10pt;" size="2"&gt;&amp;#160;(telavancin). Raw materials include VIBATIV&lt;/font&gt;&lt;font style="POSITION: relative; FONT-SIZE: 6.5pt; TOP: -3pt;" size="1"&gt;&amp;#174;&lt;/font&gt;&lt;font style="FONT-SIZE: 10pt;" size="2"&gt;&amp;#160;active pharmaceutical ingredient (&amp;#8220;API&amp;#8221;) and other raw materials. Work-in-process and finished goods include third party manufacturing costs and labor and indirect costs we incur in the production process. Included in inventories are raw materials and work-in-process that may be used as clinical products, which are charged to R&amp;amp;D expense when consumed. In addition, under certain commercialization agreements, we may sell VIBATIV&lt;/font&gt;&lt;font style="POSITION: relative; FONT-SIZE: 6.5pt; TOP: -3pt;" size="1"&gt;&amp;#174;&lt;/font&gt;&lt;font style="FONT-SIZE: 10pt;" size="2"&gt;&amp;#160;packaged in unlabeled vials that are recorded in work-in-process. Inventories are stated at the lower of cost or market value. We determine the cost of inventory using the average-cost method for validation batches. We analyze our inventory levels quarterly and write down any inventory that is expected to become obsolete, that has a cost basis in excess of its expected net realizable value or for inventory quantities in excess of expected requirements.&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;b&gt;&lt;i&gt;&lt;font style="FONT-STYLE: italic; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2"&gt;Revenue Recognition&lt;/font&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Revenue is recognized when the four basic criteria of revenue recognition are met: (1)&amp;#160;persuasive evidence of an arrangement exists; (2)&amp;#160;delivery has occurred or services have been rendered; (3)&amp;#160;the fee is fixed or determinable; and (4)&amp;#160;collectability is reasonably assured. Determination of criteria (3)&amp;#160;and (4)&amp;#160;are based on management&amp;#8217;s judgments regarding the nature of the fee charged for products or services delivered and the collectability of those fees. Where the revenue recognition criteria are not met, we defer the recognition of revenue by recording deferred revenue until such time that all criteria are met.&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;i&gt;&lt;font style="FONT-STYLE: italic; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Product Revenues&lt;/font&gt;&lt;/i&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;We sell VIBATIV&lt;/font&gt;&lt;font style="POSITION: relative; FONT-SIZE: 6.5pt; TOP: -3pt;" size="1"&gt;&amp;#174;&lt;/font&gt;&lt;font style="FONT-SIZE: 10pt;" size="2"&gt;&amp;#160;in the U.S. through a limited number of distributors, and title and risk of loss transfer upon receipt by these distributors. Healthcare providers order VIBATIV&lt;/font&gt;&lt;font style="POSITION: relative; FONT-SIZE: 6.5pt; TOP: -3pt;" size="1"&gt;&amp;#174;&lt;/font&gt;&lt;font style="FONT-SIZE: 10pt;" size="2"&gt;&amp;#160;through these distributors. Commencing in the first quarter of 2014, we record revenue on the sale of VIBATIV&lt;/font&gt;&lt;font style="POSITION: relative; FONT-SIZE: 6.5pt; TOP: -3pt;" size="1"&gt;&amp;#174;&lt;/font&gt; &lt;font style="FONT-SIZE: 10pt;" size="2"&gt;on a sell-through basis, once the distributors sell the product to healthcare providers.&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Product sales are recorded net of estimated government-mandated rebates and chargebacks, distribution fees, estimated product returns and other deductions. We reflect such reductions in revenue as either an allowance to the related account receivable from the distributor, or as an accrued liability, depending on the nature of the sales deduction. Sales deductions are based on management&amp;#8217;s estimates that consider payer mix in target markets, industry benchmarks and experience to date. We monitor inventory levels in the distribution channel, as well as sales of VIBATIV&lt;/font&gt;&lt;font style="POSITION: relative; FONT-SIZE: 6.5pt; TOP: -3pt;" size="1"&gt;&amp;#174;&lt;/font&gt;&lt;font style="FONT-SIZE: 10pt;" size="2"&gt;&amp;#160;by distributors to healthcare providers, using product-specific data provided by the distributors. Product return allowances are based on amounts owed or to be claimed on related sales. These estimates take into consideration the terms of our agreements with customers, historical product returns of VIBATIV&lt;/font&gt;&lt;font style="POSITION: relative; FONT-SIZE: 6.5pt; TOP: -3pt;" size="1"&gt;&amp;#174;&lt;/font&gt;&lt;font style="FONT-SIZE: 10pt;" size="2"&gt;&amp;#160;experienced by Theravance&amp;#8217;s former collaborative partner, Astellas, rebates or discounts taken, estimated levels of inventory in the distribution channel, the shelf life of the product, and specific known market events, such as competitive pricing and new product introductions. We update our estimates and assumptions each quarter and if actual future results vary from our estimates, we may adjust these estimates, which could have an effect on product sales and earnings in the period of adjustment.&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;i&gt;&lt;u&gt;&lt;font style="FONT-STYLE: italic; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Sales Discounts:&lt;/font&gt;&lt;/u&gt;&lt;/i&gt;&lt;font style="FONT-SIZE: 10pt;" size="2"&gt;&amp;#160; We offer cash discounts to our customers, generally 2% of the sales price, as an incentive for prompt payment. We expect our customers to comply with the prompt payment terms to earn the cash discount. We account for cash discounts by reducing accounts receivable by the full amount and recognizing the discount as a reduction of revenue in the same period the related revenue is recognized.&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;i&gt;&lt;u&gt;&lt;font style="FONT-STYLE: italic; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Chargebacks and Government Rebates:&lt;/font&gt;&lt;/u&gt;&lt;/i&gt;&lt;font style="FONT-SIZE: 10pt;" size="2"&gt;&amp;#160; For VIBATIV&lt;/font&gt;&lt;font style="POSITION: relative; FONT-SIZE: 6.5pt; TOP: -3pt;" size="1"&gt;&amp;#174;&lt;/font&gt;&lt;font style="FONT-SIZE: 10pt;" size="2"&gt;&amp;#160;sales in the U.S., we estimate reductions to product sales for qualifying federal and state government programs including discounted pricing offered to Public Health Service (PHS) as well as government-managed Medicaid programs. Our reduction for PHS is based on actual chargebacks that distributors have claimed for reduced pricing offered to such health care providers. Our accrual for Medicaid is based upon statutorily-defined discounts, estimated payer mix, expected sales to qualified healthcare providers, and our expectation about future utilization. The Medicaid accrual and government rebates that are invoiced directly to us are recorded in other accrued liabilities on the consolidated balance sheet. For qualified programs that can purchase our products through distributors at a lower contractual government price, the distributors charge back to us the difference between their acquisition cost and the lower contractual government price, which we record as an allowance against accounts receivable.&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;i&gt;&lt;u&gt;&lt;font style="FONT-STYLE: italic; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Distribution Fees and Product Returns:&lt;/font&gt;&lt;/u&gt;&lt;/i&gt;&lt;font style="FONT-SIZE: 10pt;" size="2"&gt;&amp;#160; We have written contracts with our distributors that include terms for distribution-related fees. We record distribution-related fees based on a percentage of the product sales price. We offer our distributors a right to return product purchased directly from us, which is principally based upon the product&amp;#8217;s expiration date. Additionally, we have granted more expansive return rights to our distributors following our product launch of VIBATIV&lt;/font&gt;&lt;font style="POSITION: relative; FONT-SIZE: 6.5pt; TOP: -3pt;" size="1"&gt;&amp;#174;&lt;/font&gt;&lt;font style="FONT-SIZE: 10pt;" size="2"&gt;. We will generally accept product returns during the six months prior to and twelve months after the product expiration date on product that had been sold to our distributors. Product returned is generally not resalable given the nature of our products and method of administration. We have developed estimates for VIBATIV&lt;/font&gt;&lt;font style="POSITION: relative; FONT-SIZE: 6.5pt; TOP: -3pt;" size="1"&gt;&amp;#174;&lt;/font&gt;&lt;font style="FONT-SIZE: 10pt;" size="2"&gt;&amp;#160;product returns based upon historical VIBATIV&lt;/font&gt;&lt;font style="POSITION: relative; FONT-SIZE: 6.5pt; TOP: -3pt;" size="1"&gt;&amp;#174;&lt;/font&gt;&lt;font style="FONT-SIZE: 10pt;" size="2"&gt;&amp;#160;sales from Theravance&amp;#8217;s former collaborative partner, Astellas. We record distribution fees and product returns as an allowance against accounts receivable.&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;i&gt;&lt;u&gt;&lt;font style="FONT-STYLE: italic; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Allowance for Doubtful Accounts:&lt;/font&gt;&lt;/u&gt;&lt;/i&gt;&lt;font style="FONT-SIZE: 10pt;" size="2"&gt;&amp;#160; We maintain a policy to record allowances for potentially doubtful accounts for estimated losses resulting from the inability of our customers to make required payments. As of March&amp;#160;31, 2014 and December&amp;#160;31, 2013, there was no allowance for doubtful accounts as we have not had any write-offs historically.&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;i&gt;&lt;font style="FONT-STYLE: italic; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Collaborative Arrangements and Multiple-Element Arrangements&lt;/font&gt;&lt;/i&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Revenue from nonrefundable, up-front license or technology access payments under license and collaborative arrangements that are not dependent on any future performance by us is recognized when such amounts are earned. If we have continuing obligations to perform under the arrangement, such fees are recognized over the estimated period of continuing performance obligation.&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;We account for multiple element arrangements, such as license and development agreements in which a customer may purchase several deliverables, in accordance with Financial Accounting Standards Board (&amp;#8220;FASB&amp;#8221;) Accounting Standards Codification (&amp;#8220;ASC&amp;#8221;) Subtopic 605-25, &amp;#8220;Multiple Element Arrangements.&amp;#8221; For new or materially amended multiple element arrangements, we identify the deliverables at the inception of the arrangement and each deliverable within a multiple deliverable revenue arrangement is accounted for as a separate unit of accounting if both of the following criteria are met: (1)&amp;#160;the delivered item or items have value to the customer on a standalone basis and (2)&amp;#160;for an arrangement that includes a general right of return relative to the delivered item(s), delivery or performance of the undelivered item(s)&amp;#160;is considered probable and substantially in our control. We allocate revenue to each non-contingent element based on the relative selling price of each element. When applying the relative selling price method, we determine the selling price for each deliverable using vendor-specific objective evidence (&amp;#8220;VSOE&amp;#8221;) of selling price, if it exists, or third-party evidence (&amp;#8220;TPE&amp;#8221;) of selling price, if it exists. If neither VSOE nor TPE of selling price exist for a deliverable, we use the best estimated selling price for that deliverable. Revenue allocated to each element is then recognized based on when the basic four revenue recognition criteria are met for each element.&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;For multiple-element arrangements entered into prior to January&amp;#160;1, 2011, we determined the delivered items under our collaborative arrangements did not meet the criteria to be considered separate accounting units for the purposes of revenue recognition. As a result, we recognized revenue from non-refundable, upfront fees and development contingent payments in the same manner as the final deliverable, which is ratably over the expected term of our performance of R&amp;amp;D services under the agreements. These upfront or contingent payments received, pending recognition as revenue, are recorded as deferred revenue and are classified as a current or non-current liability on the consolidated balance sheets and recognized over the estimated period of performance. We periodically review the estimated performance periods of our contracts based on the progress of our programs.&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Where a portion of non-refundable upfront fees or other payments received are allocated to continuing performance obligations under the terms of a collaborative arrangement, they are recorded as deferred revenue and recognized as revenue or as an accrued liability and recognized as a reduction of R&amp;amp;D expenses ratably over the term of our estimated performance period under the agreement. We determine the estimated performance periods, and they are periodically reviewed based on the progress of the related program. The effect of any change made to an estimated performance period and, therefore revenue recognized, would occur on a prospective basis in the period that the change was made.&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Under certain collaborative arrangements, we have been reimbursed for a portion of our R&amp;amp;D expenses. These reimbursements have been reflected as a reduction of R&amp;amp;D expense in our consolidated statements of operations, as we do not consider performing research and development services to be a part of our ongoing and central operations. Therefore, the reimbursement of research and developmental services and any amounts allocated to our research and development services are recorded as a reduction of R&amp;amp;D expense.&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Amounts deferred under a collaborative arrangement in which the performance obligations are terminated will result in an immediate recognition of any remaining deferred revenue and accrued liability in the period that termination occurred, provided that there are no remaining performance obligations.&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;We account for contingent payments in accordance with FASB Subtopic ASC 605-28 &amp;#8220;Revenue Recognition&amp;#8212;Milestone Method.&amp;#8221; We recognize revenue from milestone payments when (i)&amp;#160;the milestone event is substantive and its achievability was not reasonably assured at the inception of the agreement and (ii)&amp;#160;we do not have ongoing performance obligations related to the achievement of the milestone. Milestone payments are considered substantive if all of the following conditions are met: the milestone payment (a)&amp;#160;is commensurate with either our performance to achieve the milestone or the enhancement of the value of the delivered item or items as a result of a specific outcome resulting from our performance to achieve the milestone, (b)&amp;#160;relates solely to past performance, and (c)&amp;#160;is reasonable relative to all of the deliverables and payment terms (including other potential milestone consideration) within the arrangement.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
  <us-gaap:InventoryDisclosureTextBlock id="Tag169" contextRef="D2014Q1">&lt;div style="font-size:10.0pt;font-family:Times New Roman;FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2"&gt;3. Inventories&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Inventories were as follows:&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="text-align:left;TEXT-ALIGN: left; WIDTH: 727px; BORDER-COLLAPSE: collapse;" border="0" cellspacing="0" cellpadding="0" width="727"&gt;

&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 68.96%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="68%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.58%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.42%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;March&amp;#160;31,&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.58%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.42%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;December&amp;#160;31,&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.04%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 68.96%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="68%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;(In&amp;#160;thousands)&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.58%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.42%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;2014&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.58%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.42%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;2013&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.04%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 68.96%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="68%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Raw materials&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.58%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.34%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.08%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="11%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;3,997&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.58%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.34%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.08%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="11%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;5,138&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.04%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 68.96%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="68%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Work-in-process&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.58%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.42%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;2,225&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.58%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.42%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;360&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.04%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 68.96%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="68%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Finished goods&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.58%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.42%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;4,792&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.58%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.42%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;4,908&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.04%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 68.96%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="68%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Total inventories&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.58%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.34%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.08%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="11%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;11,014&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.58%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.34%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.08%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="11%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;10,406&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.04%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
  <us-gaap:InventoryRawMaterialsNetOfReserves id="Tag170" contextRef="I2014Q1" unitRef="USD" decimals="-3">3997000</us-gaap:InventoryRawMaterialsNetOfReserves>
  <us-gaap:InventoryWorkInProcessNetOfReserves id="Tag171" contextRef="I2014Q1" unitRef="USD" decimals="-3">2225000</us-gaap:InventoryWorkInProcessNetOfReserves>
  <us-gaap:InventoryFinishedGoodsNetOfReserves id="Tag172" contextRef="I2014Q1" unitRef="USD" decimals="-3">4792000</us-gaap:InventoryFinishedGoodsNetOfReserves>
  <us-gaap:InventoryRawMaterialsNetOfReserves id="Tag173" contextRef="I2013" unitRef="USD" decimals="-3">5138000</us-gaap:InventoryRawMaterialsNetOfReserves>
  <us-gaap:InventoryWorkInProcessNetOfReserves id="Tag174" contextRef="I2013" unitRef="USD" decimals="-3">360000</us-gaap:InventoryWorkInProcessNetOfReserves>
  <us-gaap:InventoryFinishedGoodsNetOfReserves id="Tag175" contextRef="I2013" unitRef="USD" decimals="-3">4908000</us-gaap:InventoryFinishedGoodsNetOfReserves>
  <us-gaap:AllocatedShareBasedCompensationExpense id="Tag176" contextRef="D2014Q2_5M_TheravanceIncMember_RestrictedStockMember_PerformanceContingentMember_SpecialLongTermRetentionAwards2011Member" unitRef="USD" decimals="-5">7000000</us-gaap:AllocatedShareBasedCompensationExpense>
  <tbph:TotalShareBasedCompensationCostNextTwelveMonths id="Tag177" contextRef="D2014Q2_M05_TheravanceIncMember_RestrictedStockMember_PerformanceContingentMember_SpecialLongTermRetentionAwards2011Member" unitRef="USD" decimals="-5">10700000</tbph:TotalShareBasedCompensationCostNextTwelveMonths>
  <tbph:LongTermRetentionProgramCashBonusExpensePaid id="Tag178" contextRef="D2014Q2_M05_TheravanceIncMember_SpecialLongTermRetentionAwards2011Member_DeferredCashBonusMember" unitRef="USD" decimals="-5">9500000</tbph:LongTermRetentionProgramCashBonusExpensePaid>
  <tbph:PercentageOfEconomicInterestInFuturePayments id="Tag179" contextRef="D2014Q2_M0601_SubsequentEventMember_SeparationAndDistributionAgreementMember_TheravanceIncMember" unitRef="Pure" decimals="2">0.85</tbph:PercentageOfEconomicInterestInFuturePayments>
  <tbph:ProceedsFromSpinOffOfBusinessesCapitalized id="Tag180" contextRef="D2014Q2_M0601_SubsequentEventMember_SeparationAndDistributionAgreementMember_TheravanceIncMember" unitRef="USD" decimals="-5">393000000</tbph:ProceedsFromSpinOffOfBusinessesCapitalized>
  <tbph:CollaborativeAgreementTerminationTerm id="Tag181" contextRef="D2014Q2_M0602_SubsequentEventMember_TransitionServicesAgreementMember_TheravanceIncMember_MaximumMember">P2Y</tbph:CollaborativeAgreementTerminationTerm>
  <tbph:ExpectedPeriodWithinWhichMajorityOfServicesProvidedUnderAgreement id="Tag182" contextRef="D2014Q2_M0602_SubsequentEventMember_TransitionServicesAgreementMember_TheravanceIncMember_MinimumMember">P6M</tbph:ExpectedPeriodWithinWhichMajorityOfServicesProvidedUnderAgreement>
  <tbph:ExpectedPeriodWithinWhichMajorityOfServicesProvidedUnderAgreement id="Tag183" contextRef="D2014Q2_M0602_SubsequentEventMember_TransitionServicesAgreementMember_TheravanceIncMember_MaximumMember">P12M</tbph:ExpectedPeriodWithinWhichMajorityOfServicesProvidedUnderAgreement>
  <us-gaap:SalesRevenueGoodsNet id="Tag184" contextRef="D2013Q1" unitRef="USD" decimals="-3">0</us-gaap:SalesRevenueGoodsNet>
  <tbph:CollaborativeArrangementsRevenue id="Tag185" contextRef="D2014Q1" unitRef="USD" decimals="-3">0</tbph:CollaborativeArrangementsRevenue>
  <us-gaap:CostOfGoodsSold id="Tag186" contextRef="D2013Q1" unitRef="USD" decimals="-3">0</us-gaap:CostOfGoodsSold>
  <us-gaap:IncreaseDecreaseInAccountsReceivable id="Tag187" contextRef="D2013Q1" unitRef="USD" decimals="-3">0</us-gaap:IncreaseDecreaseInAccountsReceivable>
  <us-gaap:ProceedsFromSaleAndCollectionOfNotesReceivable id="Tag188" contextRef="D2014Q1" unitRef="USD" decimals="-3">0</us-gaap:ProceedsFromSaleAndCollectionOfNotesReceivable>
  <us-gaap:IncomeTaxExpenseBenefit id="Tag189" contextRef="D2013Q1" unitRef="USD" decimals="0">0</us-gaap:IncomeTaxExpenseBenefit>
  <tbph:CommonStockStockDividendRatio id="Tag190" contextRef="D2014Q2_M0602" unitRef="Pure" decimals="INF">0.286</tbph:CommonStockStockDividendRatio>
  <us-gaap:CommonStockDividendsShares id="Tag191" contextRef="D2014Q2_M0602" unitRef="Shares" decimals="INF">32260105</us-gaap:CommonStockDividendsShares>
  <tbph:LongTermRetentionProgramCashBonusMaximumPotentialExpensePaidAfterModification id="Tag192" contextRef="D2014Q2_M05_TheravanceIncMember_SpecialLongTermRetentionAwards2011Member_DeferredCashBonusMember" unitRef="USD" decimals="-5">11200000</tbph:LongTermRetentionProgramCashBonusMaximumPotentialExpensePaidAfterModification>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized id="Tag193" contextRef="I2014Q2_M0531_TheravanceIncMember_RestrictedStockMember_PerformanceContingentMember_SpecialLongTermRetentionAwards2011Member_MaximumMember" unitRef="USD" decimals="-5">24500000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
</xbrli:xbrl>